

## AHA SCIENTIFIC STATEMENT

# Hypertension in Pregnancy: Diagnosis, Blood Pressure Goals, and Pharmacotherapy: A Scientific Statement From the American Heart Association

Vesna D. Garovic, MD, PhD, FAHA, Chair; Ralf Dechend, MD; Thomas Easterling, MD; S. Ananth Karumanchi, MD; Suzanne McMurtry Baird, DNP, RN; Laura A. Magee, MD, FRCPC; Sarosh Rana, MD, MPH; Jane V. Vermunt, MChB, MSc; Phyllis August, MD, MPH, FAHA, Vice Chair; on behalf of the American Heart Association Council on Hypertension; Council on the Kidney in Cardiovascular Disease, Kidney in Heart Disease Science Committee; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Lifestyle and Cardiometabolic Health; Council on Peripheral Vascular Disease; and Stroke Council

**ABSTRACT:** Hypertensive disorders of pregnancy (HDP) remain one of the major causes of pregnancy-related maternal and fetal morbidity and mortality worldwide. Affected women are also at increased risk for cardiovascular disease later in life, independently of traditional cardiovascular disease risks. Despite the immediate and long-term cardiovascular disease risks, recommendations for diagnosis and treatment of HDP in the United States have changed little, if at all, over past decades, unlike hypertension guidelines for the general population. The reasons for this approach include the question of benefit from normalization of blood pressure treatment for pregnant women, coupled with theoretical concerns for fetal well-being from a reduction in utero-placental perfusion and in utero exposure to antihypertensive medication. This report is based on a review of current literature and includes normal physiological changes in pregnancy that may affect clinical presentation of HDP; HDP epidemiology and the immediate and long-term sequelae of HDP; the pathophysiology of preeclampsia, an HDP commonly associated with proteinuria and increasingly recognized as a heterogeneous disease with different clinical phenotypes and likely distinct pathological mechanisms; a critical overview of current national and international HDP guidelines; emerging evidence that reducing blood pressure treatment goals in pregnancy may reduce maternal severe hypertension without increasing the risk of pregnancy loss, high-level neonatal care, or overall maternal complications; and the increasingly recognized morbidity associated with postpartum hypertension/preeclampsia. Finally, we discuss the future of research in the field and the pressing need to study socioeconomic and biological factors that may contribute to racial and ethnic maternal health care disparities.

**Key Words:** AHA Scientific Statements ■ cardiovascular diseases ■ diagnosis ■ hypertension ■ pregnancy ■ therapeutics

Hypertensive disorders of pregnancy (HDP) encompass chronic hypertension, gestational hypertension, preeclampsia/eclampsia, and preeclampsia superimposed on chronic hypertension.<sup>1</sup> The diagnostic criteria for HDP in the United States have evolved over the past 5 decades<sup>1</sup>; the most current definition of hypertension in pregnancy from the American College of Obstetricians and Gynecologists (ACOG) was published in 2013,<sup>1</sup> with updates and recommendations made in 2019 and 2020 (Table S1 and Table S2 in the Supplemental Material).<sup>2,3</sup> Most guidelines around the world are

aligned in defining hypertension in pregnancy as blood pressure (BP)  $\geq 140/90$  mmHg (see the Treatment of Hypertension in Pregnancy section). There is variability in the threshold for initiating antihypertensive treatment attributable to uncertainty about the maternal benefits of lowering BP and the potential fetal risks from medication-induced reductions in utero-placental circulation and in utero exposure to antihypertensive medications.<sup>2</sup> In contrast, diagnostic and treatment thresholds for the general population have evolved over the years<sup>4,5</sup>; in the 2017 American College of Cardiology/American Heart

Supplemental material is available with this article at <https://www.ahajournals.org/doi/suppl/10.1161/HYP.000000000000208>

© 2021 American Heart Association, Inc.

Hypertension is available at [www.ahajournals.org/journal/hyp](http://www.ahajournals.org/journal/hyp)

**Table 1. Immediate Maternal and Fetal Complications of HDP**

	Effect estimate (95% CI)
<b>Maternal outcomes</b>	
<b>Mortality</b>	
Chronic hypertension	aOR, 1.7 (1.2–2.4) <sup>13</sup>
Preeclampsia	OR, 2.7 (1.0–7.1) <sup>14*</sup> aOR, 2.6 (2.1–3.4) <sup>13</sup>
Preeclampsia superimposed on chronic hypertension	aOR, 2.3 (1.5–3.6) <sup>13</sup>
<b>Myocardial infarction</b>	
Chronic hypertension	aOR, 3.4 (2.2–5.1) <sup>13</sup>
Gestational hypertension	aOR, 1.0 (0.5–2.2) <sup>13</sup>
Preeclampsia	aOR, 3.0 (2.0–4.6) <sup>13</sup>
Preeclampsia superimposed on chronic hypertension	aOR, 5.2 (3.1–8.7) <sup>13</sup>
<b>Stroke</b>	
Chronic hypertension	aOR, 3.4 (2.8–4.1) <sup>13</sup>
Gestational hypertension	aOR, 1.4 (1.1–1.8) <sup>13</sup> aOR, 1.6 (1.1–2.3) <sup>15</sup>
Preeclampsia	aOR, 5.7 (5.0–6.5) <sup>13</sup> aOR, 7.1 (5.3–9.6) <sup>15</sup>
Preeclampsia superimposed on chronic hypertension	aOR, 7.8 (6.3–9.8) <sup>13</sup>
Eclampsia	aOR, 65.9 (43.6–99.6) <sup>15</sup>
<b>Peripartum cardiomyopathy</b>	
HDP	aOR, 3.2 (2.1–4.9), White women <sup>16</sup> aOR, 4.0 (2.3–7.1), Black women <sup>16</sup> aOR, 3.0 (1.3–7.0), Hispanic women <sup>16</sup>
Chronic hypertension	aOR, 3.8 (3.3–4.3) <sup>13</sup>
Gestational hypertension	aOR, 1.7 (1.5–2.1) <sup>13</sup>
Preeclampsia	aOR, 3.3 (2.9–3.7) <sup>13</sup>
Preeclampsia superimposed on chronic hypertension	aOR, 4.4 (3.6–5.3) <sup>13</sup>
SCAD	7.6% higher prevalence of preeclampsia in women with SCAD vs US women of childbearing age <sup>17</sup>
<b>Fetal/neonatal outcomes</b>	
<b>SGA (birth weight &lt;10th centile)</b>	
HDP	RR, 1.6 (1.5–1.6) <sup>18</sup>
Severe hypertension	OR, 1.8 (1.2–2.6) <sup>19</sup>
Preeclampsia	OR, 1.5 (1.0–2.2) <sup>19</sup>
<b>Stillbirth</b>	
HDP	RR, 1.4 (1.1–1.8) <sup>18</sup>
Chronic hypertension	aOR, 1.7 (1.6–1.8) <sup>13</sup>
Preeclampsia	aOR, 1.3 (1.2–1.3) <sup>13</sup>
Preeclampsia superimposed on chronic hypertension	aOR, 1.8 (1.7–1.9) <sup>13</sup>
<b>Preterm delivery (&lt;37 wk)</b>	
Chronic hypertension	aOR, 1.3 (1.2–1.3) <sup>13</sup>
Severe hypertension	OR, 2.6 (1.8–3.7) <sup>19</sup>
Preeclampsia	OR, 3.5 (2.5–4.9) <sup>19</sup> aOR, 3.1 (3.0–3.1) <sup>13</sup>
Preeclampsia superimposed on chronic hypertension	aOR, 4.7 (4.5–4.8) <sup>13</sup>

(Continued)

**Table 1. Continued**

	Effect estimate (95% CI)
<b>Preterm delivery (&lt;34 wk)</b>	
Severe hypertension	OR, 3.1 (2.0–4.8) <sup>19</sup>
Preeclampsia	OR, 2.6 (1.6–4.2) <sup>19</sup>
<b>Placental abruption</b>	
Chronic hypertension	aOR, 1.4 (1.4–1.5) <sup>13</sup>
Gestational hypertension	aOR, 1.1 (1.1–1.2) <sup>13</sup>
Preeclampsia	aOR, 2.3 (2.2–2.3) <sup>13</sup>
Preeclampsia superimposed on chronic hypertension	aOR, 2.2 (2.1–2.4) <sup>13</sup>
<b>Postpartum hemorrhage</b>	
Chronic hypertension	aOR, 1.3 (1.2–1.3) <sup>13</sup>
Gestational hypertension	aOR, 1.5 (1.4–1.5) <sup>13</sup>
Preeclampsia	aOR, 2.3 (2.2–2.4) <sup>13</sup>
Preeclampsia superimposed on chronic hypertension	aOR, 1.7 (1.6–1.7) <sup>13</sup>

Effect estimates are unadjusted unless specified as ARR/aOR. Different studies have adjusted for different variables; for specifics, please refer to the original references. Comparison groups are women who had normotensive pregnancies.

aOR indicates adjusted odds ratio; ARR, absolute risk reduction; HDP, hypertensive disorders of pregnancy; OR, odds ratio; RR, risk ratio; SCAD, spontaneous coronary artery dissection; and SGA, small for gestational age.

\*The study end point was a composite of mortality and other serious complications.

Association (AHA) Hypertension Clinical Practice Guidelines, the threshold for the diagnosis of stage 1 hypertension was further lowered to 130/80 from 140/90 mm Hg<sup>6</sup> on the basis of observational studies and clinical trials demonstrating reduced cardiovascular disease (CVD) events with treatment to lower levels.<sup>7,8</sup>

This scientific statement presents a synthesis of the scientific evidence (from literature published until August 31, 2020) that is relevant to the current controversies concerning HDP diagnostic and treatment strategies. It is a timely statement given that current trends indicate that the incidence of HDP continues to increase<sup>9,10</sup> as a result of advanced age at first pregnancy and increased prevalence of obesity and other cardiometabolic risk factors. CVD, including cerebrovascular accidents and cardiomyopathy, now accounts for up to half of all maternal deaths.<sup>11</sup> Pregnancy-related stroke hospitalizations increased >60% from 1994 to 2011, and HDP-associated stroke rates increased 2-fold compared with non-HDP-related stroke.<sup>10</sup> Thus, in the discussion that follows, we emphasize the need for future research aimed at recognizing and appropriately treating HDP.

## EPIDEMIOLOGY

HDP are the second leading cause of global maternal mortality behind maternal hemorrhage<sup>12</sup> and are a significant cause of short- and long-term maternal and fetal/offspring morbidity (Tables 1 and 2). Elevated systolic BPs throughout pregnancy, even below the diagnostic

**Table 2. Long-Term Maternal and Offspring Complications of HDP**

	Effect estimate (95% CI)
<b>Maternal outcome</b>	
<b>Hypertension (≥140/90 mmHg)</b>	
HDP	HR, 2.3 (1.9–2.8) <sup>20</sup> OR, 11.6 (10.6–12.7) <sup>21</sup>
Preeclampsia	aHR, 4.5 (4.3–4.6) <sup>22</sup> aHR, 2.2 (2.1–2.3) <sup>22</sup> RR, 3.1 (2.5–3.9) <sup>23</sup> RR, 3.7 (2.7–5.1) <sup>24</sup> OR, 3.4 (3.1–5.0) <sup>25</sup>
<b>Type 2 diabetes</b>	
HDP	HR, 1.8 (1.5–2.1) <sup>20</sup> OR, 2.0 (1.7–2.4) <sup>21</sup> HR, 1.4 (1.3–1.7) <sup>26</sup>
Preeclampsia	aHR, 1.8 (1.6–1.9) <sup>22</sup> OR, 2.14 (1.5–3.0) <sup>25</sup>
<b>Hyperlipidemia</b>	
HDP	HR, 1.3 (1.4–1.5) <sup>20</sup> OR, 1.5 (1.3–1.7) <sup>21</sup>
Preeclampsia	aHR, 1.3 (1.3 to 1.4) <sup>22</sup>
<b>Subclinical markers of vascular damage</b>	
Augmentation index	Weighted mean difference, 5.5% (1.6%–9.4%) <sup>27</sup>
Carotid intima-media test	Weighted mean difference, 0.02 mm (0.00–0.04) <sup>27</sup> >0.77 mm; aOR, 3.2 (1.1–9.1) <sup>28</sup>
Carotid–femoral pulse wave velocity	Weighted mean difference, 0.6 m/s (0.2–1.1) <sup>27</sup>
Arterial stiffness index	Unadjusted difference, 0.32 m/s (0.13–0.51) <sup>21</sup>
<b>CVD*</b>	
Gestational hypertension	aHR, 1.4 (1.1–1.9) <sup>29†</sup> OR, 1.7 (1.3–2.2) <sup>30</sup>
Preeclampsia	aHR, 1.7 (1.3–2.1) <sup>29</sup> HR, 1.7 (1.6–1.8) <sup>31</sup> OR, 1.7 (2.5–3.0) <sup>30</sup>
Preeclampsia with severe features	OR, 2.7 (2.5–3.0) <sup>30</sup>
Early-onset preeclampsia (<34 wk of gestation)	aHR, 4.9 (3.0–7.8) <sup>32</sup> OR, 5.6 (1.5–21.4) <sup>25</sup>
<b>Coronary heart disease</b>	
HDP	aHR, 1.9 (1.4–2.5) <sup>29</sup> HR, 1.7 (1.3–2.3) <sup>20</sup> HR, 1.8 (1.3–2.6) <sup>21</sup>
Preeclampsia	aHR, 2.1 (1.5–3.0) <sup>29</sup> HR, 1.7 (1.5–1.8) <sup>31</sup> RR, 2.5 (1.4–4.4) <sup>33</sup>
<b>Heart failure</b>	
HDP	aHR, 1.5 (1.3–1.9) <sup>31</sup> HR, 2.7 (1.6–4.6) <sup>20</sup> HR, 1.7 (1.0–2.6) <sup>21</sup>
Preeclampsia	aHR, 2.1 (1.6–2.8) <sup>31</sup> aHR, 2.0 (1.1–3.7) <sup>28</sup> RR, 4.2 (2.1–8.4) <sup>33</sup>

(Continued)

**Table 2. Continued**

	Effect estimate (95% CI)
<b>Atrial fibrillation</b>	
HDP	HR, 1.4 (1.1–1.6) <sup>20</sup>
Preeclampsia	aHR, 1.7 (1.4–2.2) <sup>31</sup>
<b>All stroke</b>	
HDP	aHR, 1.8 (1.6–2.1) <sup>31</sup> HR, 1.9 (1.3–2.6) <sup>20</sup>
Preeclampsia	aHR, 1.9 (1.5–2.4) <sup>31</sup> aHR, 1.5 (1.1–2.1) <sup>29</sup> RR, 1.8 (1.3–2.6) <sup>33</sup>
Ischemic hemorrhage	aHR, 1.7 (1.4–2.1) <sup>31</sup>
Intracerebral hemorrhage	aHR, 1.7 (1.2–2.4) <sup>31</sup>
Subarachnoid hemorrhage	aHR, 2.0 (1.6–2.5) <sup>31</sup>
<b>Vascular dementia</b>	
Gestational hypertension	aHR, 3.0 (2.1–4.3) <sup>34</sup>
Preeclampsia	aHR, 2.4 (1.8–3.2) <sup>34</sup> HR, 3.5 (2.0–6.1) <sup>35</sup>
<b>Chronic kidney disease</b>	
Gestational hypertension	RR, 1.5 (1.1–2.0) <sup>36</sup>
Preeclampsia	RR, 2.3 (1.5–3.5) <sup>36</sup>
<b>End-stage kidney disease</b>	
Gestational hypertension	RR, 3.6 (2.3–5.7) <sup>36</sup>
Preeclampsia	RR, 6.6 (2.7–14.8) <sup>36</sup>
<b>Venous thromboembolism</b>	
HDP	OR, 1.5 (1.2–1.9) <sup>21</sup>
Gestational hypertension	aHR, 1.4 (1.3–1.5) <sup>37</sup>
Preeclampsia	aHR, 1.6 (1.4–2.0) <sup>37</sup>
<b>Offspring outcome</b>	
<b>CVD‡</b>	
Severe preeclampsia, term delivery	aHR, 2.3 (1.1–4.7) <sup>38</sup>
<b>Stroke</b>	
Gestational hypertension	HR, 1.4 (1.0–1.8) <sup>39</sup>
Preeclampsia	HR, 1.9 (1.2–3.0) <sup>39</sup>
<b>BMI</b>	
Preeclampsia	Mean difference, 0.36 kg/m <sup>2</sup> (0.04–0.68) <sup>40</sup>
<b>Hypertension (≥140/90 mmHg)</b>	
Gestational hypertension	SBP, 2.0 mmHg (1.4–2.7) <sup>41</sup> DBP, 1.1 mmHg (0.6–1.5) <sup>41</sup>
Preeclampsia	SBP, 5.2 mmHg (1.6–8.7) <sup>40</sup> DBP, 4.1 mmHg (0.7–7.4) <sup>40</sup>


All effect estimates are unadjusted unless specified as aHR. Different studies have adjusted for different variables; for specifics, please refer to the original references. Comparison groups are women who had normotensive pregnancies.

aHR indicates adjusted hazard ratio; aOR, adjusted odds ratio; BMI, body mass index; CVD, cardiovascular disease; DBP, diastolic blood pressure; HDP, hypertensive disorders of pregnancy; HR, hazard ratio; OR, odds ratio; RR, risk ratio; and SBP, systolic blood pressure.

\*CVD included ischemic/hypertensive heart disease or stroke.

†Chronic hypertension was included as a CVD end point in this study.

‡CVD included cardiomyopathy, hypertension, pulmonary heart disease, arrhythmia, or heart failure.



**Figure. Pathogenesis of HDP.**

Preexisting maternal comorbidities, nonmodifiable patient characteristics, reproductive history, and genetic and immune factors increase the risk of developing a hypertensive disorder of pregnancy (HDP). The molecular and pathophysiological mechanisms of preeclampsia are largely unknown, but the cause is likely a combination of, and interaction between, factors from both maternal and placental pathways.<sup>61</sup> Variable contributions of the underlying maternal and placental pathophysiological pathways result in the heterogeneous phenotypes of HDP. The associated widespread endovascular damage and dysfunction may be long-lasting with a possible intergenerational effect. (Continued)

threshold for hypertension, also are associated with increased risk of preterm delivery and infants who are small for gestational age and have low birth weight.<sup>42,43</sup>

Traditionally, the incidence of HDP was reported on a per-pregnancy basis to assist prediction of pregnancy-related complications (both maternal and fetal) in an obstetric clinical setting (Table 1). However, the HDP population-based incidence expressed per pregnancy (7.5%) underestimates the number of women affected by this condition during their reproductive years (15.3%).<sup>20</sup> Per-woman rather than per-pregnancy incidence provides better assessment of the number of women at risk for future CVD on the basis of their reproductive histories,<sup>30</sup> including development of diabetes and hypertension<sup>20,21</sup> (Table 2).

It is well accepted that hypertension develops significantly more frequently after HDP, but studies indicate that hypertension also develops faster in women with HDP and is diagnosed up to 10 years earlier compared with women with normotensive pregnancies,<sup>20,26,44–46</sup> although the precise timing requires further examination. Earlier onset of cardiometabolic risk factors and CVD events,<sup>22,31,44</sup> as well as higher rates of accumulated chronic conditions and multimorbidity,<sup>20</sup> supports the thesis of accelerated aging among women who have a history of HDP.<sup>20,21,47</sup>

## PATHOPHYSIOLOGY OF HDP

### Hemodynamic Changes in Normal Pregnancy and Preeclampsia

Systemic vascular resistance decreases while plasma volume and cardiac output increase during pregnancy. There is a physiological drop in BP, often detectable before the end of the first trimester,<sup>48,49</sup> attributable to vasodilation.<sup>50</sup> Meta-analyses and high-quality longitudinal studies found that compared with BP at 10 or 12 weeks, the BP drop during the second trimester was on average 1 to 2 mm Hg.<sup>51–53</sup> There is wide interindividual variability, and BP trajectories likely relate to preexisting maternal health factors<sup>53</sup> such as chronic hypertension and require further clarification. Renal blood flow and glomerular filtration rate increase by 50% in normal pregnancy but are ≈30% lower in women with preeclampsia as a result of both decreases in renal blood flow and the ultrafiltration coefficient, attributable to endotheliosis in the glomerular capillary bed.<sup>54</sup> Plasma volume increases

in normal pregnancy, and earlier studies have suggested that it may be decreased in women with preeclampsia.<sup>55</sup> However, multiple longitudinal and cross-sectional studies in preeclamptic women have demonstrated that suppressed plasma renin activity, high BP, decreased glomerular filtration rate, and frequent development of edema are more consistent with an overfilled, vasoconstricted circulation rather than true hypovolemia and underfilling.<sup>56</sup> Cardiometabolic changes in normal pregnancy are more pronounced in women who develop preeclampsia and include increased insulin resistance, total cholesterol, triglycerides, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol.<sup>57</sup> Hypercoagulability, a feature of normal pregnancy, may be exaggerated in preeclampsia and is caused by increased thrombin generation, fibrinogen, and activated protein C resistance and reduced protein S and fibrinolysis.<sup>58</sup>

### Abnormal Placentation and the Pathogenesis of the Maternal Preeclampsia Syndrome

The diameter of the uterine spiral arteries increases greatly during normal pregnancy as a result of remodeling of the endothelium and vascular smooth muscle, stimulated by release of proteases from endovascular trophoblast and uterine natural killer cells.<sup>59</sup> Failure of spiral artery remodeling (ie, retention of smooth muscle) is a feature of preeclampsia<sup>60,61</sup> and leads to decreased utero-placental perfusion, demonstrated by noninvasive blood flow and perfusion studies using Doppler ultrasound or magnetic resonance imaging (Figure).<sup>61</sup>

Placental pathology attributable to rheological consequences includes villous architectural changes caused by turbulent jets entering the intervillous space at rates of 1 to 2 m/s (10–20 times normal), causing the rupture of anchoring villi and the formation of echogenic cystic lesions that are visible by ultrasound.<sup>64</sup> In addition, retention of vascular smooth muscle preserves the ability of spontaneous vasoconstriction and ischemia-reperfusion injury, which may result in oxidative stress.

Alterations in angiogenic factors are recognized as a likely consequence of abnormal placentation occurring in early pregnancy. Increased circulating soluble fms-like tyrosine kinase 1, an antiangiogenic factor of placental origin, leads to neutralization and decrease of proangiogenic factors such as placental growth factor and vascular

**Figure Continued.** In podocyturia, the urinary loss of podocytes (glomerular epithelial cells) in preeclamptic women contributes to the development of proteinuria and has been documented both before and at the time of preeclampsia diagnosis.<sup>62</sup> Senescence is an irreversible cell-cycle arrest mechanism that leads to systematic metabolic and functional decline and may play a role in impaired angiogenesis in preeclampsia.<sup>63</sup> ACE indicates angiotensin-converting enzyme; AKI, acute kidney injury; Ang, angiotensin; AT1-AA, angiotensin II receptor 1 autoantibodies; ATR1, angiotensin II type 1 receptor; CAD, coronary artery disease; CKD, chronic kidney disease; CO, cardiac output; DIC, disseminated intravascular coagulation; ESKD, end-stage kidney disease; ET-1, endothelin-1; FGR, fetal growth restriction; GFR, glomerular filtration rate; HF, heart failure; IL, interleukin; MI, myocardial infarction; PCM, peripartum cardiomyopathy; PIGF, placental growth factor; PRES, posterior reversible encephalopathy syndrome; RAS, renin angiotensin system; ROS, reactive oxygen species; SASP, senescence-associated secretory phenotype; SCAD, spontaneous coronary artery dissection; sENG, soluble endoglin; sFlt1, soluble fms-like tyrosine kinase 1; SGA, small for gestational age; Th-1, type 1 T helper cell; TNF- $\alpha$ , tumor necrosis factor- $\alpha$ ; TPR, total peripheral resistance; uNK, uterine natural killer cell; VEGF, vascular endothelial growth factor; and VTE, venous thromboembolism.

endothelial growth factor, which then contribute to the hypertension and glomerulopathy characteristic of the maternal syndrome.<sup>61</sup> Measurements of angiogenic biomarkers have been incorporated into risk stratification in several innovative therapeutic trials for preeclampsia prevention<sup>65,66</sup> but are not routinely used to guide clinical care in most countries, including the United States. An increased soluble fms-like tyrosine kinase 1/placental growth factor ratio may be particularly pronounced in women with early (<34 gestational weeks), severe preeclampsia, which has been designated by some as placental preeclampsia<sup>67</sup> because of the association between placental ischemia and adverse fetal outcomes (fetal growth restriction in particular). Preeclampsia occurring later in pregnancy, labeled maternal preeclampsia by some, has been associated with more pronounced maternal vascular dysfunction before pregnancy (secondary to hypertension, diabetes, or obesity), less pronounced placental pathology, and fewer fetal complications. In maternal preeclampsia, pregnancy acts as a physiological stress test that exacerbates preexisting endothelial dysfunction. This underscores the heterogeneity of HDP, whereby the extremes of clinical subtypes (early versus late, mild versus severe, and presence or absence of fetal growth restriction) may reflect distinct underlying mechanisms.<sup>67</sup> Sharp discrimination between maternal and placental preeclampsia is overly simplistic and artificial because both processes likely play a role but with varying contributions. Regardless of the clinical subtype, diagnosis and treatment of hypertension remain a mainstay of the prevention of immediate maternal complications and permanent cardiovascular injury, together with seizure prevention with magnesium sulfate.

## PREVENTION OF PREECLAMPSIA AND ADVERSE MATERNAL AND FETAL OUTCOMES

Preconception health and its impact on both pregnancy outcomes and future health have gained attention.<sup>68</sup> Lifestyle changes before and during pregnancy may ameliorate both maternal and fetal risks. A meta-analysis of 44 randomized controlled trials reported that dietary interventions reduce maternal gestational weight gain and improve pregnancy outcomes.<sup>69</sup> Exercise may reduce gestational hypertension and preeclampsia risk by  $\approx$ 30 and 40%, respectively.<sup>70,71</sup> The first Canadian guideline for physical activity throughout pregnancy published in 2019 recommends that all women without contraindication should be physically active during pregnancy.<sup>72</sup> Low-dose aspirin, starting between 12 and 16 weeks of gestation, reduces the risk of preeclampsia and related adverse outcomes by 10% to 20% in women at increased risk (Table 3).<sup>97,99–101</sup> The ACOG recommends daily low-dose aspirin for women with a history of early-onset preeclampsia and preterm delivery or for women with >1 pregnancy complicated by preeclampsia.<sup>97</sup>

The optimal dose of aspirin has not been formally tested, with most trials using 81 to 150 mg daily.<sup>100</sup> Promising results from experimental studies and a pilot trial of pravastatin<sup>102,103</sup> need to be critically viewed because of concerns related to fetal safety. Experimental evidence suggests that metformin may prevent preeclampsia by reducing soluble fms-like tyrosine kinase 1 and soluble endoglin secretion from primary endothelial tissue and through senomorphic mechanisms.<sup>63,104,105</sup> Clinical studies have indicated that metformin may reduce the odds of gestational hypertension in women with gestational diabetes and that it may prevent preeclampsia.<sup>106</sup>

## BP MEASUREMENT IN PREGNANCY

Accurate BP measurement is crucial for classifying hypertension and initiating treatment, regardless of pregnancy status. Because mercury sphygmomanometers are less available, aneroid devices are commonly used, although they require calibration and are less accurate. Several oscillometric automated devices have been validated in pregnant women, including those with gestational hypertension and preeclampsia.<sup>107</sup>

Although most current guidelines recommend hypertension management based on office BP in pregnancy, for the general population, out-of-office BP measurements are widely endorsed as more accurate and better predictors of cardiovascular morbidity and mortality.<sup>6,108</sup> Although several studies report BP levels during pregnancy using self-measured BP or ambulatory BP monitoring, current data describing appropriate out-of-office cutoffs for HDP diagnosis are limited.<sup>109</sup> The ACOG and the International Society for the Study of Hypertension in Pregnancy recommend the use of self-measured BP in women with chronic or gestational hypertension, particularly when uncontrolled.<sup>1,110</sup> Available information does not demonstrate a systematic difference between self-measurements and office BP measurements in pregnancy, which suggests that appropriate treatment and diagnostic thresholds for self-monitoring during pregnancy may be equivalent to standard clinic thresholds; however, additional information on appropriate methodology and validation of devices is needed.

## Nonsustained Hypertension

White coat hypertension is reported in 25% of the non-pregnant adult population. Its prevalence in pregnancy is less certain, ranging from 4% to 30%.<sup>2</sup> According to 24-hour BP measurements, 32% of women with hypertension had white coat hypertension, but just 8% were diagnosed as such.<sup>111</sup> A meta-analysis of studies addressing white coat hypertension reported increased risks of preeclampsia and adverse fetal outcomes compared with women with normotension. Risks were lower compared with women with sustained chronic or gestational hypertension.<sup>81</sup> The frequency and clinical significance of

**Table 3. Risk Factors for Preeclampsia**

Risk factors	Effect estimate (95% CI)
<b>High*</b>	
Prior preeclampsia	RR, 8.4 (7.1–9.9) <sup>73</sup>
Chronic stage 2 hypertension (≥140/90 mm Hg)	RR, 5.1 (4.0–6.5) <sup>73</sup>
Pregestational diabetes	RR, 3.7 (3.1–4.3) <sup>73</sup>
Multifetal pregnancy	RR, 2.9 (2.6–3.1) <sup>73</sup>
Antiphospholipid syndrome	RR, 2.8 (1.8–4.3) <sup>73</sup>
Systemic lupus erythematosus	RR, 2.5 (1.0–6.3) <sup>73</sup>
Chronic kidney disease	OR, 10.4 (6.3–17.1) <sup>74</sup>
<b>Moderate*</b>	
Maternal age >35 y	RR, 1.2 (1.1–1.3) <sup>73</sup>
Prepregnancy BMI >30 kg/m <sup>2</sup>	aOR, 3.7 (3.5–3.9) <sup>75</sup> RR, 2.8 (2.6–3.1) <sup>73</sup>
Family history (first-degree relative)	RR, 2.9 (1.7–4.9) <sup>76</sup>
Race (Black)	aHR, 1.6 (1.5–1.6) <sup>77</sup> HR, 2.2 (1.9–2.6), early onset <sup>78</sup> HR, 1.3 (1.2–1.4), late onset <sup>78</sup>
Low socioeconomic status	aOR, 4.91 (1.9–12.5) <sup>79</sup>
Nulliparity	RR, 2.1 (1.9–2.4) <sup>73</sup>
History of adverse pregnancy outcome:	
Stillbirth	RR, 2.4 (1.7–3.4) <sup>73</sup>
Placental abruption	RR, 2.0 (1.4–2.7) <sup>73</sup>
<b>Other</b>	
Chronic hypertension (130–134/80–84 mm Hg)	aOR, 2.2 (1.9–2.5), mild <sup>80</sup> aOR, 2.7 (2.0–3.5), severe <sup>80</sup>
Chronic hypertension (135–139/85–90 mm Hg)	aOR, 2.7 (2.3–3.2), mild <sup>80</sup> aOR, 3.8 (2.8–5.1), severe <sup>80</sup>
Severe hypertension	OR, 6.1 (4.4–8.5) <sup>19</sup>
White coat hypertension	RR, 2.4 (1.2–4.8) <sup>81</sup>
Prepregnancy BMI >25 kg/m <sup>2</sup>	RR, 2.1 (2.0–2.2) <sup>73</sup>
Insulin resistance >75th centile	aOR, 1.9 (1.1–3.2) <sup>82</sup>
Gestational diabetes	aOR, 1.6 (1.4–1.9) <sup>83</sup>
Recovered acute kidney injury	aOR, 2.9 (1.9–4.4) <sup>84</sup>
Hyperthyroidism	aOR, 1.8 (1.1–2.9) <sup>85</sup>
Hydatidiform mole	OR, 10.1 (3.4–30.0) <sup>86</sup>
Fetus with trisomy 13	Incidence with 24%–44% vs without 2%–8% <sup>87</sup>
<b>Genetic susceptibility<sup>88,89</sup></b>	
Assisted reproductive technology	RR, 1.8 (1.6–2.1) <sup>73</sup>
Oocyte donation	OR, 4.3 (3.1–6.1) <sup>90</sup>
New paternity	OR, 2.3 (1.2–4.4) <sup>91</sup>
Pregnancy interval >4 y	OR, 1.1 (1.0–1.2), recurrent preeclampsia <sup>92</sup> OR, 2.1 (1.3–3.3) <sup>91</sup>
Migraine	OR, 2.1 (1.5–2.9) <sup>93</sup>

ACOG indicates American College of Obstetricians and Gynecologists; aHR, adjusted hazard ratio; aOR, adjusted odds ratio; BMI, body mass index; HR, hazard ratio; OR, odds ratio; and RR, relative risk.

Other risk factors are based on an emerging number of factors that may increase risk of preeclampsia. Cohabitation of >12 months<sup>94</sup> and smoking<sup>95,96</sup> have an inverse association with preeclampsia risk. All estimates are unadjusted unless specified as aHR/aOR. Different studies have adjusted for different variables; for specifics, please refer to the original references. Comparison groups are women without the risk factor of interest.

\*Classification of risk factors as high or moderate is based on the ACOG recommendations for aspirin therapy to prevent preeclampsia. Therapy is indicated when ≥1 high or ≥2 moderate risk factors are present.<sup>97,98</sup>

†Based on the 2017 Hypertension Clinical Practice Guidelines.<sup>6</sup>

masked hypertension in pregnancy have not been extensively studied. Any category of nonsustained BP elevation in pregnancy can progress to sustained hypertension and requires follow-up. Self-measured BP is important for diagnosing nonsustained BP elevations, including masked hypertension and white coat hypertension, that occur before 20 weeks of gestation. For clinical purposes, the definition of hypertension in pregnancy requires 2 elevated BP measurements 4 hours apart (Table S1).

### BP Variation

In the nonpregnant population, the association between BP variation, independent of baseline BP, and CVD risk is mixed, although greater variability is more convincingly associated with increased stroke risk.<sup>112–118</sup> Limited small studies of gestational short-term and visit-to-visit BP variation suggest that greater variation is associated with adverse maternal and perinatal outcomes,<sup>119,120</sup> but evidence is currently inconclusive, and there is need for consensus on the methodology for the measurement of BP variability in pregnancy.

Standard gestational age-specific BPs and centiles can assist in clinical interpretation of BP changes from expected levels.<sup>53,120</sup> Nationally representative, population-specific gestational BP references have been reported from China and the United Kingdom.<sup>49,51</sup> Studies addressing the association of BP changes in relation to healthy BP standards with maternal and perinatal outcomes are needed.

### Secondary Hypertension

Most (≈90%) women with chronic hypertension have primary hypertension. Secondary hypertension may occur in a small proportion of women and is associated with worse maternal and fetal outcomes. It should be considered if maternal age is <35 years, hypertension is severe or resistant, there is no family history of hypertension, or there are suggestive laboratory features such as hypokalemia, elevated creatinine, or albuminuria early in pregnancy (Table S3).<sup>121,122</sup> Last, the prevalence of obesity in women of reproductive age has increased in recent years, and obstructive sleep apnea may play an increasing role in secondary hypertension among pregnant women.<sup>123,124</sup> Because there are no pregnancy-specific guidelines for obstructive sleep apnea treatment, pregnant women with sleep apnea should be managed concurrently with a sleep medicine specialist for application of available diagnostic and therapeutic methods, depending on the stage of pregnancy.

### Postpartum Hypertension and Postpartum Preeclampsia

Postpartum hypertension and postpartum preeclampsia are not specifically included in the classification of HDP, but there is increasing awareness of their significance,

as documented in the 2013 ACOG executive summary that implemented changes in clinical practice through closer postpartum monitoring and visits.<sup>125</sup> These entities are particularly important for 2 reasons. First, ≈60% of all maternal deaths occur within the first year postpartum, and HDP remain one of the leading causes of maternal mortality.<sup>126</sup> Second, postpartum hypertension offers an opportunity to use medications and to achieve BP goals without limitations related to their potential negative impacts on the fetus. The prevalence of postpartum hypertension may be as high as 8% in women without antepartum hypertension (followed up 48 hours after delivery and up to 6 weeks postpartum) and up to 50% in women with a history of preeclampsia 6 to 12 weeks after delivery.<sup>127,128</sup> The distinction between postpartum aggravation of antepartum HDP and de novo postpartum preeclampsia (also called delayed-onset postpartum preeclampsia) is unclear. Further research addressing underlying mechanisms is needed to clarify appropriate treatment and the need for magnesium sulfate for seizure prevention. The duration ranges from days to 3 months, contributing to serious short-term maternal complications such as stroke, seizures, and cardiomyopathy and metabolic dysregulation such as insulin resistance and weight gain.<sup>127,128</sup> Patient education is an important tool for early recognition of symptoms and signs. Novel approaches such as remote hypertension monitoring programs have potential to improve compliance and early diagnosis of postpartum hypertension and preeclampsia.<sup>129</sup>

The rate of elevation in the antepartum soluble fms-like tyrosine kinase 1/placental growth factor ratio is an independent predictor of hypertension that persists postpartum.<sup>130</sup> Furthermore, preeclampsia-associated endothelial dysfunction and altered cerebrovascular autoregulation have been shown to persist postpartum<sup>131</sup> and may amplify postpartum hypertension risk. Intravenous fluids, mobilization of extravascular fluid, and use of nonsteroidal anti-inflammatory drugs for postpartum analgesia may contribute to its occurrence. A recent randomized controlled clinical trial has shown that postpartum use of furosemide in women with HDP was associated with a 60% reduction in persistent hypertension at day 7 after delivery (adjusted relative risk, 0.40).<sup>132</sup> If these findings can be implemented in the clinic, there is significant opportunity to reduce maternal morbidity in the postpartum period and to avoid unnecessary hospitalization. In nonpregnant individuals, there is abundant evidence that nonsteroidal anti-inflammatory drugs are associated with clinically significant increases in BP.<sup>133–135</sup> A recent systematic review and meta-analysis that included 5 randomized controlled trials and 5 retrospective cohorts concluded that compared with acetaminophen, nonsteroidal anti-inflammatory drugs were not associated with increased BPs up to discharge (2–4 days postpartum).<sup>136</sup> The authors considered the quality of evidence to be low

because of the small sample sizes, imprecise results, and short duration of follow-up. Additional investigation is needed to address the impact of longer duration of postpartum nonsteroidal anti-inflammatory drug use in older women with chronic hypertension and additional renal and cardiovascular risk factors.<sup>137,138</sup>

## TREATMENT OF HYPERTENSION IN PREGNANCY

### Current BP Goals for Pregnant Patients

The recent American College of Cardiology/AHA task force guidelines lowered the threshold for the diagnosis of hypertension in nonpregnant patients to 130/80 mmHg for stage 1 hypertension and to 140/90 mmHg for stage 2 hypertension, resulting in larger numbers of individuals being diagnosed and treated.<sup>6</sup> There is robust evidence in the general population demonstrating reduced CVD risk with treatment to lower levels.<sup>7</sup> Indeed, most cardiovascular events occur in individuals with BP levels of 140 to 159/90 to 109 mmHg.<sup>139</sup> Even younger individuals with hypertension demonstrate early vascular remodeling and endothelial dysfunction, particularly in smaller arteries and arterioles, which leads to progressive stiffening of larger blood vessels and organ damage if hypertension is untreated.<sup>140,141</sup> For all HDP, hypertension is defined internationally as a BP ≥140/90 mmHg, although treatment thresholds and targets vary (Table 4).

The recommendations of published guidelines addressing diagnosis and treatment of HDP are summarized in Table 4. Differences among societies further demonstrate confusion in the field, which likely contributes to a failure to move forward. The ACOG recommends antihypertensive therapy for women with preeclampsia and a sustained systolic BP ≥160 mmHg or diastolic BP ≥110 mmHg and with chronic hypertension at a systolic BP ≥160 mmHg or diastolic BP ≥110 mmHg, with a treatment goal of 120 to 160/80 to 110 mmHg.<sup>2</sup> Internationally, the majority of hypertension societies endorse a more aggressive approach for antihypertensive treatment, recommending therapy when BP is ≥140/90 mmHg.<sup>110,142–144,149,151</sup> Therapeutic targets similar to the American College of Cardiology/AHA target of 130/80 mmHg<sup>6</sup> are recommended by the International Society for the Study of Hypertension in Pregnancy,<sup>110</sup> Hypertension Canada Guidelines,<sup>146,149</sup> National Institute for Health and Care Excellence,<sup>144</sup> and World Health Organization.<sup>143</sup> The following question arises: Why are the diagnostic and treatment BP thresholds higher in the United States compared with those recommended for nonpregnant individuals and compared with the majority of international guidelines addressing HDP?

Determining the optimal BP threshold in pregnancy for antihypertensive treatment and therapeutic targets requires a balance between the prevention of maternal hypertensive complications and the avoidance of fetal



**Table 4. Summary and Key Features of Published Guidelines for the Diagnosis and Treatment of HDP**

Guideline	Hypertension in pregnancy diagnosis*	Treatment threshold, mmHg	Treatment target, mmHg	Continuation of antihypertensive therapy
ACOG 2013 <sup>1</sup> 2019 <sup>2</sup> 2020 <sup>3</sup>	≥160/105 with diagnosis of chronic hypertension <sup>1</sup> ≥160/110 if acute <sup>2</sup> /chronic hypertension <sup>2†</sup>	Not specified <sup>‡</sup>	120–159/80–105 <sup>1</sup> 120–159/80–109 if chronic <sup>2†</sup>	Guided by informed discussion with women
World Health Organization 2018 <sup>42</sup> 2020 <sup>1,43</sup>	Not defined	≥140/90	Above lower limits of normal <sup>1,43</sup> ≤135/85	Not specified Continue treatment unless <110/70 mmHg or symptomatic hypotension
National Institute for Health and Care Excellence 2018 <sup>45</sup> 2020 <sup>1,46</sup>	Plus the absence of preeclampsia features	≥140/90 <sup>45,146</sup>	DBP, 85 <sup>45,146</sup> <140/90+comorbidities <sup>1,45</sup>	Not specified
International Society for the Study of Hypertension in Pregnancy 2018 <sup>10</sup>	Plus the absence of preeclampsia features	≥140/90 in office ≥135/85 at home	110–140/85	Not specified
European Society of Cardiology 2018 <sup>47</sup>	*Antenatally unclassified <sup>†</sup> if first BP measure >20 wk of gestation	≥150/95 ≥140/90+end-organ damage/gestational hypertension	Not specified	Consider discontinuation if BP 140–159/90–109 mmHg+normal renal function
Society of Obstetric Medicine of Australia and New Zealand 2014 <sup>48</sup>		≥160/100 ≥140/90, optional	Based on clinician assessment	Consider discontinuation if BP fall <20 wk of gestation
<b>Guideline</b>	<b>Preeclampsia diagnosis§</b>	<b>Superimposed preeclampsia on chronic hypertension diagnosis§</b>	<b>Treatment thresh-old, mmHg</b>	<b>Treatment target, mmHg</b>
ACOG 2019 <sup>2</sup>	Symptoms include utero-placental dysfunction	Chronic hypertension+sudden change in preeclampsia diagnostic parameters	≥160/110 <sup>2</sup>	Not specified
National Institute for Health and Care Excellence 2019 <sup>44</sup>	Symptoms include utero-placental dysfunction	Not specified	≥140/90	≤135/85
Society of Obstetricians and Gynaecologists, Canada 2014 <sup>45</sup> 2018 <sup>49</sup>	Symptoms include ≥1 severe complications	≥20 wk of gestation+resistant hypertension+new or worsening proteinuria or ≥1 adverse conditions or severe complications of preeclampsia	≥140/90 <sup>49</sup>	DBP, 85 <sup>49</sup>
International Society for the Study of Hypertension in Pregnancy 2018 <sup>10</sup>	Symptoms include utero-placental dysfunction†	Chronic essential hypertension+≥1 sign of maternal organ dysfunction consistent with preeclampsia, or new-onset proteinuria in the setting of a rise in BP	≥140/90	110–140/85
European Society of Cardiology 2018 <sup>47</sup>	Proteinuria necessary, only high suspicion if hypertension+abnormal biochemistry/symptomatic	Hypertension <20 wk of gestation+superimposed gestational hypertension+proteinuria	≥140/90	Not specified
Society of Obstetric Medicine of Australia and New Zealand 2014 <sup>48</sup>	Symptoms include fetal growth restriction	Preexisting hypertension with proteinuria or ≥1 systemic features of preeclampsia	160/100 140–160/90–100, optional	Individual assessment

(Continued)

**Table 4. Continued**

Guideline	Future CVD risk management
ACOG	2019 <sup>150</sup> Postpartum follow-up visit (early postpartum visit) with either the primary care professional or cardiologist is recommended within 7–10 d of delivery for women with hypertensive disorders
National Institute for Health and Care Excellence	2019 <sup>144</sup> Referral to family care doctor for CVD risk prevention
Society of Obstetricians and Gynaecologists, Canada	2014 <sup>145</sup> All women who have had HDP should pursue a healthy diet and lifestyle
International Society for the Study of Hypertension in Pregnancy	2018 <sup>110</sup> Regular general practitioner follow-up to monitor BP+periodic measurement of fasting lipids and blood sugar. Adopt healthy lifestyle with maintenance of ideal weight and regular aerobic exercise
European Society of Cardiology	2018 <sup>147</sup> Annual primary care physician CVD risk screen
Society of Obstetric Medicine of Australia and New Zealand	2014 <sup>146</sup> Advise optimization of CVD risk factors

ACOG indicates American College of Obstetricians and Gynecologists; BP, blood pressure; CVD, cardiovascular disease; DBP, diastolic blood pressure; and HDP, hypertensive disorders of pregnancy.

\*Systolic BP  $\geq 140$  mm Hg+DBP  $\geq 90$  mm Hg; gestational hypertension,  $>20$  weeks of gestation+previously normal BP; chronic/preexisting hypertension,  $<20$  weeks of gestation. †ACOG guidelines state to consider a lower treatment threshold for chronic hypertension if comorbidities or renal failure is present and to consult with other subspecialties about antihypertensive treatment BP targets, although this is not specified in the recommendations.<sup>2</sup>

#World Health Organization recommendations state that "women with nonsevere hypertension during pregnancy should be offered antihypertensive drug treatment in the context of good quality antenatal care follow-up"<sup>143</sup> and that "women with severe hypertension during pregnancy should receive treatment with antihypertensive drugs."<sup>142</sup>

\$All guidelines require systolic BP  $\geq 140$  mm Hg+DBP  $\geq 90$  mm Hg  $>20$  weeks of gestation+previously normal BP  $\geq 1$  proteinuria/abnormal renal or liver function tests or platelet count/symptoms and signs consistent with end-organ damage of preeclampsia. ||Utero-placental dysfunction: fetal growth restriction, abnormal umbilical artery Doppler waveform analysis, or stillbirth.

risks. The US (ACOG) guidelines are influenced by at least 3 debated issues. First is the prevailing perspective, based on small studies, that there are no measurable immediate or long-term health benefits of stricter BP treatment for the relatively short duration of pregnancy (4–9 months, depending on type of HDP) in young women without other CVD risks. Second, there are concerns that lowering maternal BP may compromise utero-placental circulation and negatively affect fetal well-being and growth. Third, therapeutic options are limited because of concerns about potential adverse fetal effects, particularly malformations from intrauterine exposure to antihypertensive medications. Furthermore, discrepancies among international guidelines are a reflection of the country-specific context within which they were developed. Such debate and subsequent inconsistencies in recommendations hinder progression toward consensus for optimal management of HDP internationally. For example, differences in BP thresholds for initiating antihypertensive therapy make combining results from observational studies of antihypertensive therapy for meta-analysis more challenging.

### BP Goals for Pregnant Patients: Emerging Data, Limitations, and Current Controversies

There are several compelling reasons to consider lower BP thresholds. First, more aggressive treatment of hypertension in pregnancy prevents the development of severe hypertension, as demonstrated by both a systematic review of randomized trials<sup>152</sup> and CHIPS (Control of Hypertension in Pregnancy Study), in which the average BP achieved by tight control was 133/85 mm Hg.<sup>14</sup> Although comparison of less tight versus tight control showed no effect on rates of preeclampsia, the former group demonstrated a higher risk of thrombocytopenia and elevated liver enzyme levels, markers of disease severity. In addition, in this trial and elsewhere, tight control may have decreased the risk of preterm birth.<sup>153</sup> The importance of severe hypertension as an outcome has been questioned,<sup>19</sup> although exploratory analyses of the CHIPS data (adjusted for allocated group and prognostic factors) showed that severe hypertension is a surrogate marker for adverse maternal and perinatal outcomes, independently of and similar in magnitude to preeclampsia.<sup>14,19</sup> This is especially relevant in high-risk populations such as Black women for whom the risk of hypertension-related adverse outcomes is high.<sup>154</sup> A study of Black women with chronic hypertension showed that using antihypertensives before 20 weeks of gestation and achieving a BP  $<140/90$  mm Hg were associated with lower incidences of superimposed preeclampsia and preterm delivery  $<35$  weeks compared with women with BP  $\geq 140/90$  mm Hg.<sup>155</sup> Furthermore, lower ( $<140/90$  mm Hg) versus higher ( $\geq 140/90$  mm Hg) BP levels during pregnancy have been associated with lower rates of preeclampsia, including preeclampsia with severe features, and lower rates of preterm delivery.<sup>153</sup> Lower rates of

preeclampsia with treatment of hypertension reported by these most recent studies are in sharp contrast to the majority of previous studies indicating that treatment of hypertension does not prevent preeclampsia. Whether there is a difference between women with chronic hypertension (who were preferentially recruited in these 2 studies indicating benefit) and those with gestational hypertension remains unknown; the answer will require prospective, adequately powered studies. On the basis of results of retrospective studies, including one showing benefit of tighter BP control<sup>156</sup> and another indicating that malignant/uncontrolled hypertension in the nonpregnant state has changes in the brain similar to those from eclampsia,<sup>157</sup> a large randomized controlled trial, the CHAP Project (Chronic Hypertension and Pregnancy), is nearing completion in the United States (ClinicalTrials.gov identifier: NCT02299414). The CHAP project is comparing outcomes between pregnant women with chronic hypertension who are given antihypertensive treatment to maintain BP <140/90 mmHg with women given no treatment unless BP is  $\geq$ 160/105 mmHg.

Second, there is evidence that the pathophysiology of the neurological manifestations (headaches, visual disturbances, seizures) of preeclampsia is similar to that of the posterior reversible leukoencephalopathy syndrome.<sup>158</sup> Women with preeclampsia may be more susceptible to severe neurological outcomes such as intracerebral hemorrhage at lower systolic BPs (eg, 150–170 mmHg)<sup>157</sup> compared with nonpregnant subjects, thus raising the possibility that lowering BP below current targets (eg, <150/90 mmHg) may prevent these rare but devastating outcomes.<sup>157</sup>

Third, treatment of nonsevere hypertension in pregnancy (eg, BPs 140–155/90–109 mmHg) may permit prolongation of pregnancy in women without other severe features of preeclampsia who would require delivery.

Fourth, ACOG guidelines recommend withholding antihypertensive therapy for patients with preeclampsia unless BP approaches 160/110 mmHg. They also recommend urgent delivery for women with severe features of preeclampsia, which include uncontrollable hypertension with BP  $\geq$ 160/110 mmHg, even for pregnancies <34 gestational weeks, unless high-level care is available in facilities with adequate maternal and neonatal intensive care resources.<sup>3,110,159</sup> Lowering thresholds for treatment may allow timely BP control and avoidance of rushed deliveries that commonly lead to prematurity and related complications.

Fifth, the classic view that young women with hypertension without other CVD risk factors are at low short-term CVD risk from untreated hypertension during the duration of pregnancy is challenged by current epidemiological and demographic trends toward advanced age at first pregnancy and higher CVD risk (subclinical or diagnosed).<sup>9,160–162</sup> This could also be relevant among women with multiple pregnancies, who may spend several years of their lives either pregnant or breastfeeding with uncontrolled hypertension. In addition, modern fertility techniques facilitate pregnancy in women with preexisting conditions

associated with elevated CVD risk (eg, diabetes, chronic kidney disease, and polycystic ovary syndrome). Preexisting chronic kidney disease and heart disease are present in 3% and 1% to 4% of pregnancies in high-income countries, respectively.<sup>163</sup> Several guidelines consequently endorse more aggressive treatment in these women.<sup>147,148</sup>

Finally, there is abundant evidence that HDP are associated with increased risk of both immediate and postpartum complications (such as acute cardiovascular and cerebrovascular disease)<sup>164</sup> and future maternal vascular disease (Table 2). Whether better management of BP during pregnancy will lead to lower rates of morbidity related to hypertension in the immediate postpartum period is not known. Traditional CVD risk factors (eg, obesity, hypertension, diabetes, hyperlipidemia) are associated with increased risk of HDP,<sup>73</sup> but the associations between HDP and future CVD, renal disease, and vascular dementia persist, even after adjustment for such factors.<sup>31,34,36</sup> It is estimated that approximately two-thirds of HDP-associated CVD risk is mediated by established risk factors, and the remainder is likely explained by an HDP-specific pathogenesis.<sup>21,29</sup> Whether treatment of nonsevere hypertension is beneficial for preventing long-term morbidity beyond pregnancy and the puerperium remains to be demonstrated. Furthermore, evidence is needed to clarify concerns about the observed, albeit nonstatistically significant, trend toward increased small-for-gestational-age risk and decreased preterm birth in women with tight versus less tight BP control in CHIPS.<sup>165</sup> The possible risk of drug-associated fetal malformations, long-term neurodevelopmental effects on offspring,<sup>166</sup> and suggested differential effects on these outcomes by antihypertensive class<sup>152,167</sup> are all areas that require further investigation.

Given new developments in the field of hypertension outside of pregnancy that support lower BP treatment targets, together with emerging data from larger clinical trials in pregnancy, this working group supports continued investigation to determine whether BP levels similar to those recommended outside of pregnancy for the initiation of therapy and as therapeutic targets are beneficial for the mother and safe and beneficial for the fetus. While awaiting more conclusive data and trials nearing completion, we endorse informed decision-making in partnership with the patient as to whether to treat nonsevere hypertension during pregnancy to targets similar to those recommended in nonpregnant individuals. Personalization of therapy, by giving special attention to other risk factors related to hypertension-related adverse outcomes (such as preexisting heart or kidney disease, obesity, and Black race), is a rational approach.

### Antihypertensive Medications

Initial antihypertensive therapy is widely established to be monotherapy with an accepted first-line drug: labetalol or methyldopa. Some,<sup>1,110,142–144,147,149</sup> but not all,<sup>148</sup> societies

support the use of nifedipine as an initial therapy. In countries where labetalol is unavailable (eg, Germany), alternative  $\beta$ -blockers such as metoprolol or oxprenolol can be considered. These therapeutic options are based on small individual trials and are advocated by national and international clinical practice guidelines. There is no clear evidence that one drug is preferable to another according to a systematic review of randomized trials for all types of pregnancy hypertension considered together, for all antihypertensives considered together, or for  $\beta$ -blockers (including labetalol) considered separately.<sup>152</sup> However, in a separate network meta-analysis, specifically for treatment of chronic hypertension, atenolol was associated with fetal growth restriction,<sup>168</sup> especially when given for a longer duration.<sup>169</sup> These data conflict with some observational studies that have associated  $\beta$ -blocker treatment (including labetalol) with an excess of small-for-gestational-age infants, although the authors did not necessarily adjust for treatment indication and severity of maternal disease.<sup>170</sup> These conflicting data underscore a need for more fetal and newborn data on the safety of currently used antihypertensive agents in pregnancy.

Numerous clinical trials have compared various short-acting antihypertensives in the setting of acute, severe hypertension in pregnancy. The drugs most commonly examined are parenteral hydralazine, parenteral labetalol, and oral nifedipine (short, intermediate, or long acting). A Cochrane review concluded that these drugs were comparable with respect to safety and efficacy and recommended that professionals choose on the basis of experience and familiarity with a particular drug.<sup>171</sup> Most cases of severe hypertension can be successfully controlled with these drugs using doses and protocols recommended by professional societies.<sup>172</sup> In resource-poor countries, a report documented successful treatment of acute severe hypertension with oral preparations of labetalol, intermediate-acting nifedipine, and methyldopa.<sup>173</sup> Additional agents that may be considered for resistant hypertension, although not extensively studied, include nicardipine, clonidine, and furosemide.<sup>174–176</sup> Notably, diuretics, the mainstay of hypertension treatment in nonpregnant individuals, are not used often in pregnant women. This position is informed mainly by earlier studies suggesting that women with preeclampsia have lower plasma volume, suggesting that diuretics may further aggravate volume depletion and promote reactive vasoconstriction. However, older studies demonstrated their favorable safety profile in pregnancy,<sup>177</sup> and more recent guidelines have acknowledged that in women with salt-sensitive chronic hypertension or chronic kidney disease and reduced glomerular filtration rate, diuretics may be used safely, although perhaps at lower doses.<sup>2</sup> Recent studies demonstrate that they may be particularly effective in postpartum hypertension.<sup>132</sup>

The limitations of existing data on the safety of antihypertensives in pregnancy are highlighted by a systematic review of studies addressing in utero exposure to

antihypertensive medications and adverse fetal outcomes. Only 5 of 47 studies were considered high quality, and few studies reported increased odds of adverse effects in treated compared with normotensive untreated women, including congenital malformations, and effects were not uniformly observed across different studies using the same medications.<sup>166</sup> Furthermore, similar adverse events have been reported in untreated women with hypertension, leading to the conclusion that the evidence for teratogenicity of most antihypertensive agents is weak.<sup>178,179</sup>

Although first-trimester exposure to medication raises concern about structural malformations (other than those attributable to physical or vascular disruption), the fetal central nervous system develops throughout gestation and may be affected by exposures at any time point. However, no firm conclusions can be drawn about long-term child outcomes given the paucity of relevant high-quality studies.<sup>166</sup> No adverse neurodevelopmental effects have been observed for methyldopa,<sup>180</sup> nifedipine,<sup>181</sup> or atenolol,<sup>182</sup> although atenolol should be used with caution (see above). Registry data adjusted for important covariates were reassuring about the effects of preeclampsia itself; only a minimal effect was seen on standardized mathematics test scores in children from affected pregnancies at 9, 12, and 15 years of age.<sup>183</sup> In addition, when control subjects with untreated or treated hypertension have been used, children from labetalol- and methyldopa-treated women had similar IQ scores.<sup>2,14,158,184,185</sup> Small clinical trials and observational studies suggest that amlodipine, clonidine, and thiazide diuretics are probably safe in pregnancy as well.<sup>177,186,187</sup> It is also widely accepted that all renin-angiotensin system blockers should be avoided during pregnancy,<sup>188</sup> especially during the second and third trimesters when blockade of the fetal renin-angiotensin system clearly interferes with kidney development and function. Given suboptimal and frequently contradicting data on fetal safety after exposure to antihypertensive medications in utero, well-designed, carefully controlled trials are needed, with attention given to short- and long-term fetal and maternal outcomes. Last, the professionals in the field should be familiar with services offered by the Organization of Teratology Information Specialists.<sup>189</sup> The organization was founded in 1987 as a way of connecting experts in the field of birth defects research to the general public. It provides up-to-date information about the risks of medications during pregnancy and breastfeeding to patients, health care professionals, and researchers in the field of teratology.

## POSTPARTUM SCREENING

International guidelines, including those of the ACOG, the International Society for the Study of Hypertension in Pregnancy, the European Society of Cardiology, and the AHA, emphasize the need for appropriate postpartum screening and control of cardiovascular risk factors for women with a history of preeclampsia. However, the lack of studies

demonstrating efficacy and effectiveness of counseling and interventions in formerly preeclamptic women impedes the development of evidence-based guidelines. The recommendations given by different guidelines are vague and imprecise (Table 4). Randomized trials are needed to evaluate potential long-term cardiovascular benefits of early initiation of statins, aspirin, or renin-angiotensin system blockers in women with only a history of HDP as a risk factor. Lifestyle interventions addressing obesity, hypertension, and dyslipidemia are good clinical practices. Studies demonstrating the efficacy of these interventions in women of reproductive age are also needed.

## MULTIDISCIPLINARY TEAM APPROACH

Management of hypertension in pregnancy requires multidisciplinary collaborations among obstetricians, maternal fetal medicine specialists, neonatologists, nephrologists and hypertension specialists, cardiologists, anesthesiologists, pharmacists, nurses, and midwives, all of whom contribute to providing cohesive and safe preconception, antepartum, peripartum, and postpartum care. In particular, nurses and midwives in case management roles coordinate care and facilitate access to resources and services that improve health outcomes such as group prenatal care,<sup>190</sup> economic vulnerability and chronic stress risk assessments, medication adjustments, lifestyle advice, and patient education. During hospital admission, nursing recognition of maternal compromise through the use of early warning scores,<sup>191</sup> hypertension bundles, and toolkits ensures timely communication with a physician or advanced practice nurse and has been shown to reduce maternal mortality from hypertensive disorders.<sup>192</sup>

## HYPERTENSION IN PREGNANCY AND RACIAL DISPARITIES

Maternal mortality within the United States is among the highest of high-income countries, with a maternal mortality ratio of 18 per 100 000 live births.<sup>193</sup> Within the United States, racial maternal health disparities are unacceptably large. The estimated maternal mortality ratio in 2016 for White women was 13 per 100 000 live births, 30 for American Indian and Alaska Native women, and 41 for Black American women, similar to that of an upper-middle-income country.<sup>194</sup> In addition to Black, American Indian, and Alaska Native women having poorer social determinants of health, implicit racial bias is present within the US health care system, and management of severe maternal morbidity is consistently worse for these women.<sup>195</sup> HDP disproportionately affect Black, American Indian, and Alaska Native women,<sup>194,196,197</sup> predominantly because of the overall higher prevalence of CVD risk factors,<sup>198</sup> but there is also evidence to suggest

that biological factors (eg, specific genetic variants) may increase the risk of preeclampsia for Black women.<sup>199,200</sup> Furthermore, preeclampsia-related severe morbidity and mortality are higher for Black women, whereas for Hispanic women, pregnancy outcomes tend to be better than those of Black or White women of similar risk.<sup>201,202</sup>

Studies must include sufficient numbers of participants from all racial groups, especially Black women, to address maternal health disparities and to inform policy and clinical practice. We endorse studies addressing the prevention of shared risk factors for HDP and CVD and those aiming to improve antenatal and postnatal outcomes.

## CONCLUSION AND FUTURE DIRECTIVES

Evidence suggests that antihypertensive therapy for pregnancy hypertension of any type halves the incidence of severe hypertension. To some, if not many, this is sufficiently compelling to dictate a change in practice toward more aggressive treatment. This may be of particular importance in underresourced communities with less experience and low capacity to respond to hypertensive urgencies and emergencies. Of high-income countries, the United States has one of the highest hypertension-related maternal mortality rates<sup>12</sup> and increasing maternal morbidity and mortality from cardiovascular conditions and cerebrovascular accidents.<sup>10,11</sup> A lower treatment threshold than currently proposed by the ACOG has the potential to decrease serious hypertensive end-organ complications. The view that mild to moderate hypertension of short duration during pregnancy is not harmful to the mother may be further addressed by CHAP, a trial that will extend observations made in earlier trials of women with chronic hypertension that demonstrated that normalization of BP with antihypertensive treatment did not adversely affect fetal growth or neurodevelopmental outcomes. From existing data, physicians are encouraged to individualize treatment decisions, taking other risk factors into account. Future clinical trials should address questions on the optimal BP treatment thresholds and should be adequately powered to assess the effects of different BP targets on maternal and fetal/neonatal outcomes. Of note, when HDP were reclassified using the lower American College of Cardiology/AHA diagnostic threshold (systolic BP  $\geq$  130 mm Hg or diastolic BP  $\geq$  80 mm Hg), results indicated that using the lower diagnostic threshold for hypertension in pregnancy may better identify women at risk for developing preeclampsia and pregnancies at risk for adverse fetal/neonatal outcomes.<sup>203</sup>

Studies are also needed to determine adequate levels of BP control in the postpartum period given that there are no longer reservations about the impact of BP treatment on the fetus, that significant maternal morbidity and mortality occur during this time period, and that

prolonged postpartum in-hospital stay and readmissions have a significant impact on health care resources and birth experiences.

Treatment of hypertension, prevention of seizures, and timed birth with close fetal monitoring are currently the main therapeutic options for women with preeclampsia. The superiority of any of the widely used antihypertensive(s) has not been demonstrated, and combination therapies have not been tested. Although a “same drug for all” approach is practical in many settings, a more personalized approach based on patient preferences, age, race, heart rate, BP variations measured at home or in clinic, or more detailed hemodynamic assessments may be more effective in protecting women from complications of hypertensive pregnancies and possible postpregnancy CVD consequences. As timely and optimal cardiovascular risk identification and reduction cross specialties, with women of reproductive age being seen primarily by obstetrics and gynecology specialists and only later in life by internists and cardiologists, a close collaboration among these specialties should be encouraged, as advised by the AHA/ACOG presidential advisory.<sup>204</sup> Ongoing research addressing causative pathways has the potential to identify new biomarkers and novel therapeutics that target fundamental mechanisms of preeclampsia.

Last, on a global level, evidence-based consensus on diagnostic and treatment thresholds (such as  $\geq 140/90$  mm Hg), targets (keeping it  $< 140/90$  mm Hg), long-term CVD risk assessment, and HDP terminology is needed to facilitate progression in the field and to ensure that all women worldwide receive optimal care before, during, and after pregnancy. Future guidelines should avoid

integration of historical, unsubstantiated perspectives that impede improvements in women's health during pregnancy and throughout women's reproductive lives.

## ARTICLE INFORMATION

The American Heart Association makes every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel. Specifically, all members of the writing group are required to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived as real or potential conflicts of interest.

This statement was approved by the American Heart Association Science Advisory and Coordinating Committee on September 13, 2021, and the American Heart Association Executive Committee on October 14, 2021. A copy of the document is available at <https://professional.heart.org/statements> by using either “Search for Guidelines & Statements” or the “Browse by Topic” area. To purchase additional reprints, call 215-356-2721 or email [Meredith.Edelman@wolterskluwer.com](mailto:Meredith.Edelman@wolterskluwer.com)

The American Heart Association requests that this document be cited as follows: Garovic VD, Dechend R, Easterling T, Karumanchi SA, McMurtry Baird S, Magee LA, Rana S, Vermunt JV, August P; on behalf of the American Heart Association Council on Hypertension; Council on the Kidney in Cardiovascular Disease, Kidney in Heart Disease Science Committee; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Lifestyle and Cardiometabolic Health; Council on Peripheral Vascular Disease; and Stroke Council. Hypertension in pregnancy: diagnosis, blood pressure goals, and pharmacotherapy: a scientific statement from the American Heart Association. *Hypertension*. 2022;79:e21–e41. doi: 10.1161/HYP.000000000000208

The expert peer review of AHA-commissioned documents (eg, scientific statements, clinical practice guidelines, systematic reviews) is conducted by the AHA Office of Science Operations. For more on AHA statements and guidelines development, visit <https://professional.heart.org/statements>. Select the “Guidelines & Statements” drop-down menu, then click “Publication Development.”

Permissions: Multiple copies, modification, alteration, enhancement, and/or distribution of this document are not permitted without the express permission of the American Heart Association. Instructions for obtaining permission are located at <https://www.heart.org/permissions>. A link to the “Copyright Permissions Request Form” appears in the second paragraph (<https://www.heart.org/en/about-us/statements-and-policies/copyright-request-form>).

## Disclosures

### Writing Group Disclosures

Writing group member	Employment	Research grant	Other research support	Speakers' bureau/honoraria	Expert witness	Ownership interest	Consultant/advisory board	Other
Vesna D. Garovic	Mayo Clinic	Grant R01HL136348 from the National Institutes of Health†	None	None	None	None	None	None
Phyllis August	Weill Cornell Medical College Hypertension Center	None	None	None	None	None	UpToDate*	None
Ralf Dechend	HELIOS Klinikum Berlin, Experimental and Clinical Research Center (Germany)	None	None	None	None	None	None	None
Thomas Easterling	University of Washington	None	None	None	None	None	None	None
S. Ananth Karumanchi	Cedars-Sinai Medical Center	Thermo Fisher Scientific†; Siemens (research grant to study preeclampsia biomarkers for both)†	Beth Israel Deaconess Medical Center (coinventor on patents that are held by Beth Israel Deaconess Medical Center)*	None	None	Aggamin Pharmaceuticals*	Roche*	None
Laura A. Magee	King's College London (United Kingdom)	None	None	None	None	None	None	None

(Continued)

**Writing Group Disclosures Continued**

Writing group member	Employment	Research grant	Other research support	Speakers' bureau/honoraria	Expert witness	Ownership interest	Consultant/advisory board	Other
Suzanne McMurtry Baird	Clinical Concepts in Obstetrics, LLC	None	None	None	None	None	None	None
Sarosh Rana	University of Chicago	Roche (IIS)†; Siemens (IIS)†	None	None	None	None	Rochet	None
Jane V. Vermunt	Mayo Clinic	None	None	None	None	None	None	None

This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be "significant" if (a) the person receives \$10 000 or more during any 12-month period, or 5% or more of the person's gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns \$10 000 or more of the fair market value of the entity. A relationship is considered to be "modest" if it is less than "significant" under the preceding definition.

\*Modest.

†Significant.

**Reviewer Disclosures**

Reviewer	Employment	Research grant	Other research support	Speakers' bureau/honoraria	Expert witness	Ownership interest	Consultant/advisory board	Other
George Bakris	University of Chicago Medicine	None	None	None	None	None	None	None
Laxmi S. Mehta	The Ohio State University	None	None	None	None	None	None	None
Laurence Shields	Dignity Health	None	None	None	None	None	None	None
Ravi Thadhani	Harvard Medical School	Thermo Fisher (grant to Cedars-Sinai to perform diagnostics study)†; Beckman Coulter (Grant to Cedars-Sinai to perform diagnostics study)†; Siemens (grant to Cedars-Sinai to perform diagnostics study)†	None	Thermo Fisher*; Roche*	None	Mass General Brigham (patent royalties paid to my hospital based on patents on diagnostics for preeclampsia)*	None	None

This table represents the relationships of reviewers that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all reviewers are required to complete and submit. A relationship is considered to be "significant" if (a) the person receives \$10 000 or more during any 12-month period, or 5% or more of the person's gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns \$10 000 or more of the fair market value of the entity. A relationship is considered to be "modest" if it is less than "significant" under the preceding definition.

\*Modest.

†Significant.

**REFERENCES**

1. Roberts JM, August PA, Bakris G, Barton JR, Bernstein IM, Druzin ML, Gaiser RR, Granger JP, Jeyabalan A, Johnson DD, et al. Hypertension in pregnancy: report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. *Obstet Gynecol.* 2013;122:1122–1131. doi: 10.1097/01.AOG.0000437382.03963.88
2. American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 203: chronic hypertension in pregnancy. *Obstet Gynecol.* 2019;133:e26–e50. doi: 10.1097/AOG.0000000000003020
3. ACOG Practice Bulletin No. 222: gestational hypertension and preeclampsia. *Obstet Gynecol.* 2020;135:1492–1495. doi: 10.1097/AOG.0000000000003892
4. Moser M, Brown CM, Rose CH, Garovic VD. Hypertension in pregnancy: is it time for a new approach to treatment? *J Hypertens.* 2012;30:1092–1100. doi: 10.1097/HJH.0b013e3283536319
5. Scantlebury DC, Schwartz GL, Acquah LA, White WM, Moser M, Garovic VD. The treatment of hypertension during pregnancy: when should blood pressure medications be started? *Curr Cardiol Rep.* 2013;15:412. doi: 10.1007/s11886-013-0412-0
6. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APHA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines [published correction appears in *Hypertension.* 2018;71:e140–e144]. *Hypertension.* 2018;71:e13–e115. doi: 10.1161/HYP.0000000000000065
7. SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. *N Engl J Med.* 2015;373:2103–2116. doi: 10.1056/NEJMoa1511939
8. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. *Lancet.* 2002;360:1903–1913. doi: 10.1016/s0140-6736(02)11911-8
9. Ananth CV, Duzyj CM, Yadava S, Schwebel M, Tita AT, Joseph KS. Changes in the prevalence of chronic hypertension in pregnancy, United States, 1970 to 2010. *Hypertension.* 2019;74:1089–1095. doi: 10.1161/HYPERTENSIONAHA.119.12968
10. Leffert LR, Clancy CR, Bateman BT, Bryant AS, Kuklina EV. Hypertensive disorders and pregnancy-related stroke: frequency, trends, risk factors, and outcomes. *Obstet Gynecol.* 2015;125:124–131. doi: 10.1097/AOG.0000000000000590
11. Creanga AA, Syverson C, Seed K, Callaghan WM. Pregnancy-related mortality in the United States, 2011–2013. *Obstet Gynecol.* 2017;130:366–373. doi: 10.1097/AOG.0000000000002114
12. Kassebaum NJ, Barber RM, Bhutta ZA, Dandona L, Gething PW, Hay SI, Kinfu Y, Larson HJ, Liang X, Lim SS, et al. Global, regional, and national

Downloaded from http://ahajournals.org by on November 8, 2023

- levels of maternal mortality, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet*. 2016;388:1775–1812. doi: 10.1016/S0140-6736(16)31470-2
13. Wu P, Chew-Graham CA, Maas AH, Chappell LC, Potts JE, Gulati M, Jordan KP, Mamas MA. Temporal changes in hypertensive disorders of pregnancy and impact on cardiovascular and obstetric outcomes. *Am J Cardiol*. 2020;125:1508–1516. doi: 10.1016/j.amjcard.2020.02.029
  14. Magee LA, von Dadelszen P, Rey E, Ross S, Asztalos E, Murphy KE, Menzies J, Sanchez J, Singer J, Gafni A, et al. Less-tight versus tight control of hypertension in pregnancy. *N Engl J Med*. 2015;372:407–17. doi: 10.1056/NEJMoa1404595
  15. Liu S, Chan W-S, Ray JG, Kramer MS, Joseph KS. Stroke and cerebrovascular disease in pregnancy. *Stroke*. 2019;50:13–20. doi: 10.1161/STROKEAHA.118.023118
  16. Afana M, Brinjikji W, Kao D, Jackson E, Maddox T, Childers D, Eagle K, Davis M. Characteristics and in-hospital outcomes of peripartum cardiomyopathy diagnosed during delivery in the United States from the Nationwide Inpatient Sample (NIS) database. *J Card Fail*. 2016;22:512–519. doi: 10.1016/j.cardfail.2016.02.008
  17. Tweet MS, Hayes SN, Codsí E, Gulati R, Rose CH, Best PJM. Spontaneous coronary artery dissection associated with pregnancy. *J Am Coll Cardiol*. 2017;70:426–435. doi: 10.1016/j.jacc.2017.05.055
  18. Allen VM, Joseph K, Murphy KE, Magee LA, Ohlsson A. The effect of hypertensive disorders in pregnancy on small for gestational age and stillbirth: a population based study. *BMC Pregnancy Childbirth*. 2004;4:17. doi: 10.1186/1471-2393-4-17
  19. Magee LA, von Dadelszen P, Singer J, Lee T, Rey E, Ross S, Asztalos E, Murphy KE, Menzies J, Sanchez J, et al. The CHIPS randomized controlled trial (Control of Hypertension in Pregnancy Study): is severe hypertension just an elevated blood pressure? *Hypertension*. 2016;68:1153–1159. doi: 10.1161/HYPERTENSIONAHA.116.07862
  20. Garovic VD, White WM, Vaughan L, Saiki M, Parashuram S, Garcia-Valencia O, Weissgerber TL, Milic N, Weaver A, Mielke MM. Incidence and long-term outcomes of hypertensive disorders of pregnancy. *J Am Coll Cardiol*. 2020;75:2323–2334. doi: 10.1016/j.jacc.2020.03.028
  21. Honigberg MC, Zekavat SM, Aragam K, Klarin D, Bhatt DL, Scott NS, Peloso GM, Natarajan P. Long-term cardiovascular risk in women with hypertension during pregnancy. *J Am Coll Cardiol*. 2019;74:2743–2754. doi: 10.1016/j.jacc.2019.09.052
  22. Stuart JJ, Tanz LJ, Missmer SA, Rimm EB, Spiegelman D, James-Todd TM, Rich-Edwards JW. Hypertensive disorders of pregnancy and maternal cardiovascular disease risk factor development: an observational cohort study. *Ann Intern Med*. 2018;169:224–232. doi: 10.7326/M17-2740
  23. Brown MC, Best KE, Pearce MS, Waugh J, Robson SC, Bell R. Cardiovascular disease risk in women with pre-eclampsia: systematic review and meta-analysis. *Eur J Epidemiol*. 2013;28:1–19. doi: 10.1007/s10654-013-9762-6
  24. Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. *BMJ*. 2007;335:974. doi: 10.1136/bmj.39335.385301.BE
  25. Dall'Asta A, D'Antonio F, Saccone G, Buca D, Mastantuoni E, Liberati M, Flacco ME, Frusca T, Ghi T. Cardiovascular events following pregnancies complicated by pre-eclampsia with emphasis on comparison between early- and late-onset forms: systematic review and meta-analysis. *Ultrasound Obstet Gynecol*. 2021;57:698–709. doi: 10.1002/uog.22107
  26. Heida KY, Franx A, van Rijn BB, Eijkemans MJC, Boer JMA, Verschuren MWM, Oudijk MA, Bots ML, van der Schouw YT. Earlier age of onset of chronic hypertension and type 2 diabetes mellitus after a hypertensive disorder of pregnancy or gestational diabetes mellitus. *Hypertension*. 2015;66:1116–1122. doi: 10.1161/HYPERTENSIONAHA.115.06005
  27. Grand'Maison S, Pilote L, Okano M, Landry T, Dayan N. Markers of vascular dysfunction after hypertensive disorders of pregnancy: a systematic review and meta-analysis. *Hypertension*. 2016;68:1447–1458. doi: 10.1161/HYPERTENSIONAHA.116.07907
  28. Garovic VD, Milic N, Weissgerber TL, Mielke MM, Bailey KR, Lahr B, Jayachandran M, White WM, Hodis HN, Miller VM. Carotid artery intima-media thickness and subclinical atherosclerosis in women with remote histories of preeclampsia: results from a Rochester epidemiology project-based study and meta-analysis. *Mayo Clin Proc*. 2017;92:1328–1340. doi: 10.1016/j.mayocp.2017.05.030
  29. Haug EB, Horn J, Markovitz AR, Fraser A, Klykken B, Dalen H, Vatten LJ, Romundstad PR, Rich-Edwards JW, Asvold BO. Association of conventional cardiovascular risk factors with cardiovascular disease after hypertensive disorders of pregnancy: analysis of the Nord-Trøndelag Health Study. *JAMA Cardiol*. 2019;4:628–635. doi: 10.1001/jamacardio.2019.1746
  30. Grandi SM, Filion KB, Yoon S, Ayele HT, Doyle CM, Hutcheon JA, Smith GN, Gore GC, Ray JG, Nerenberg K, et al. Cardiovascular disease-related morbidity and mortality in women with a history of pregnancy complications: systematic review and meta-analysis. *Circulation*. 2019;139:1069–1079. doi: 10.1161/CIRCULATIONAHA.118.036748
  31. Leon LJM, Fergus P, Direk K, Gonzalez-Izquierdo A, Prieto-Merino D, Casas JP, Chappell L. Preeclampsia and cardiovascular disease in a large UK pregnancy cohort of linked electronic health records: a CALIBER study. *Circulation*. 2019;140:1050–1060. doi: 10.1161/CIRCULATIONAHA.118.038080
  32. Arnott C, Nelson M, Alfaro Ramirez M, Hyett J, Gale M, Henry A, Celermajer DS, Taylor L, Woodward M. Maternal cardiovascular risk after hypertensive disorder of pregnancy. *Heart*. 2020;106:1927–1933. doi: 10.1136/heartjnl-2020-316541
  33. Wu P, Haththotuwa R, Kwok CS, Babu A, Kotronias RA, Rushton C, Zaman A, Fryer AA, Kadam U, Chew-Graham CA, et al. Preeclampsia and future cardiovascular health: a systematic review and meta-analysis. *Circ Cardiovasc Qual Outcomes*. 2017;10:e003497. doi: 10.1161/CIRCOUTCOMES.116.003497
  34. Andolf E, Bladh M, Möller L, Sydsjö G. Prior placental bed disorders and later dementia: a retrospective Swedish register-based cohort study. *BJOG*. 2020;127:1090–1099. doi: 10.1111/1471-0528.16201
  35. Basit S, Wohlfahrt J, Boyd HA. Pre-eclampsia and risk of dementia later in life: nationwide cohort study. *BMJ*. 2018;363:k4109. doi: 10.1136/bmj.k4109
  36. Barrett PM, McCarthy FP, Kublickiene K, Cormican S, Judge C, Evans M, Kublickas M, Perry IJ, Stenvinkel P, Khashan AS. Adverse pregnancy outcomes and long-term maternal kidney disease: a systematic review and meta-analysis. *JAMA Netw Open*. 2020;3:e1920964. doi: 10.1001/jamanetworkopen.2019.20964
  37. Scheres LJJ, Lijfering WM, Groenewegen NFM, Koole S, de Groot CJM, Middeldorp S, Cannegieter SC. Hypertensive complications of pregnancy and risk of venous thromboembolism. *Hypertension*. 2020;75:781–787. doi: 10.1161/HYPERTENSIONAHA.119.14280
  38. Nahum Sacks K, Friger M, Shoham-Vardi I, Spiegel E, Sergienko R, Landau D, Sheiner E. Prenatal exposure to preeclampsia as an independent risk factor for long-term cardiovascular morbidity of the offspring. *Pregnancy Hypertens*. 2018;13:181–186. doi: 10.1016/j.preghy.2018.06.013
  39. Kajantie E, Eriksson JG, Osmond C, Thornburg K, Barker DJ. Preeclampsia is associated with increased risk of stroke in the adult offspring: the Helsinki Birth Cohort Study. *Stroke*. 2009;40:1176–1180. doi: 10.1161/STROKEAHA.108.538025
  40. Andraweera PH, Lassi ZS. Cardiovascular risk factors in offspring of pre-eclamptic pregnancies: systematic review and meta-analysis. *J Pediatr*. 2019;208:104–113.e6. doi: 10.1016/j.jpeds.2018.12.008
  41. Geelhoed MJ, Fraser A, Tilling K, Benfield L, Smith GD, Sattar N, Nelson SM, Lawlor DA. Preeclampsia and gestational hypertension are associated with childhood blood pressure independently of family adiposity measures. *Circulation*. 2010;122:1192–1199. doi: 10.1161/CIRCULATIONAHA.110.936674
  42. Teng H, Wang Y, Han B, Liu J, Cao Y, Wang J, Zhu X, Fu J, Ling Q, Xiao C, et al. Gestational systolic blood pressure trajectories and risk of adverse maternal and perinatal outcomes in Chinese women. *BMC Pregnancy Childbirth*. 2021;21:155. doi: 10.1186/s12884-021-03599-7
  43. Bakker R, Steegers EA, Hofman A, Jaddoe VW. Blood pressure in different gestational trimesters, fetal growth, and the risk of adverse birth outcomes: the Generation R Study. *Am J Epidemiol*. 2011;174:797–806. doi: 10.1093/aje/kwr151
  44. Haug EB, Horn J, Markovitz AR, Fraser A, Vatten LJ, Macdonald-Wallis C, Tilling K, Romundstad PR, Rich-Edwards JW, Åsvold BO. Life course trajectories of cardiovascular risk factors in women with and without hypertensive disorders in first pregnancy: the HUNT Study in Norway. *J Am Heart Assoc*. 2018;7:e009250. doi: 10.1161/JAHA.118.009250
  45. Garovic VD, Bailey KR, Boerwinkle E, Hunt SC, Weder AB, Curb D, Mosley TH Jr, Wiste HJ, Turner ST. Hypertension in pregnancy as a risk factor for cardiovascular disease later in life. *J Hypertens*. 2010;28:826–833. doi: 10.1097/HJH.0b013e3283335c29a
  46. Toher J, Chiu CL, Yeung K, Lupton SJ, Thornton C, Makris A, O'Loughlin A, Hennessy A, Lind JM. High blood pressure during pregnancy is associated with future cardiovascular disease: an observational cohort study. *BMJ Open*. 2013;3:e002964. doi: 10.1136/bmjopen-2013-002964
  47. Honigberg MC, Natarajan P. Women's cardiovascular health after hypertensive pregnancy: the long view from labor and delivery becomes clearer. *J Am Coll Cardiol*. 2020;75:2335–2337. doi: 10.1016/j.jacc.2020.01.064



48. Mahendru AA, Everett TR, Wilkinson IB, Lees CC, McEniery CM. A longitudinal study of maternal cardiovascular function from preconception to the postpartum period. *J Hypertens*. 2014;32:849–856. doi: 10.1097/HJH.000000000000090
49. Shen M, Tan H, Zhou S, Smith GN, Walker MC, Wen SW. Trajectory of blood pressure change during pregnancy and the role of pre-gravid blood pressure: a functional data analysis approach. *Sci Rep*. 2017;7:6227. doi: 10.1038/s41598-017-06606-0
50. August P, Mueller FB, Sealey JE, Edersheim TG. Role of renin-angiotensin system in blood pressure regulation in pregnancy. *Lancet*. 1995;345:896–897. doi: 10.1016/s0140-6736(95)90012-8
51. Green LJ, Mackillop LH, Salvi D, Pullon R, Loerup L, Tarassenko L, Mossop J, Edwards C, Gerry S, Birks J, et al. Gestation-specific vital sign reference ranges in pregnancy. *Obstet Gynaecol*. 2020;135:653–664. doi: 10.1097/AOG.0000000000003721
52. Loerup L, Pullon RM, Birks J, Fleming S, Mackillop LH, Gerry S, Watkinson PJ. Trends of blood pressure and heart rate in normal pregnancies: a systematic review and meta-analysis. *BMC Med*. 2019;17:167. doi: 10.1186/s12916-019-1399-1
53. Macdonald-Wallis C, Silverwood RJ, Fraser A, Nelson SM, Tilling K, Lawlor DA, de Stavola BL. Gestational-age-specific reference ranges for blood pressure in pregnancy: findings from a prospective cohort. *J Hypertens*. 2015;33:96–105. doi: 10.1097/HJH.0000000000000368
54. Lafayette RA, Druzin M, Sibley R, Derby G, Malik T, Huie P, Polhemus C, Deen WM, Myers BD. Nature of glomerular dysfunction in pre-eclampsia. *Kidney Int*. 1998;54:1240–1249. doi: 10.1046/j.1523-1755.1998.00097x
55. de Haas S, Ghossein-Doha C, van Kuijk SM, van Drongelen J, Spaanderman ME. Physiological adaptation of maternal plasma volume during pregnancy: a systematic review and meta-analysis. *Ultrasound Obstet Gynecol*. 2017;49:177–187. doi: 10.1002/uog.17360
56. Lindheimer MD, August P. Aldosterone, maternal volume status and healthy pregnancies: a cycle of differing views. *Nephrol Dial Transplant*. 2009;24:1712–1714. doi: 10.1093/ndt/gfp093
57. Spracklen CN, Smith CJ, Satlas AF, Robinson JG, Ryckman KK. Maternal hyperlipidemia and the risk of preeclampsia: a meta-analysis. *Am J Epidemiol*. 2014;180:346–358. doi: 10.1093/aje/kwu145
58. Hellgren M. Hemostasis during normal pregnancy and puerperium. *Semin Thromb Hemost*. 2003;29:125–130. doi: 10.1055/s-2003-38897
59. Bulmer JN, Williams RJ, Lash GE. Immune cells in the placental bed. *Int J Dev Biol*. 2010;54:281–294. doi: 10.1387/ijdb.082763jb
60. Lyall F, Robson SC, Bulmer JN. Spiral artery remodeling and trophoblast invasion in preeclampsia and fetal growth restriction: relationship to clinical outcome. *Hypertension*. 2013;62:1046–1054. doi: 10.1161/HYPERTENSIONAHA.113.01892
61. Rana S, Lemoine E, Granger JP, Karumanchi SA. Preeclampsia: pathophysiology, challenges, and perspectives. *Circ Res*. 2019;124:1094–1112. doi: 10.1161/CIRCRESAHA.118.313276
62. Garovic VD. The role of the podocyte in preeclampsia. *Clin J Am Soc Nephrol*. 2014;9:1337–1340. doi: 10.2215/CJN.05940614
63. Suvakov S, Cubro H, White WM, Butler Tobah YS, Weissgerber TL, Jordan KL, Zhu XY, Woollard JR, Chebib FT, Milic NM, et al. Targeting senescence improves angiogenic potential of adipose-derived mesenchymal stem cells in patients with preeclampsia. *Biol Sex Differ*. 2019;10:49. doi: 10.1186/s13293-019-0263-5
64. Burton GJ, Woods AW, Jauniaux E, Kingdom JC. Rheological and physiological consequences of conversion of the maternal spiral arteries for uteroplacental blood flow during human pregnancy. *Placenta*. 2009;30:473–482. doi: 10.1016/j.placenta.2009.02.009
65. Rolnik DL, Wright D, Poon LC, O’Gorman N, Syngelaki A, de Paco Matallana C, Akolekar R, Cicero S, Janga D, Singh M, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. *N Engl J Med*. 2017;377:613–622. doi: 10.1056/NEJMoa1704559
66. Duhig KE, Myers J, Seed PT, Sparkes J, Lowe J, Hunter RM, Shennan AH, Chappell LC; PARROT Trial Group. Placental growth factor testing to assess women with suspected pre-eclampsia: a multicentre, pragmatic, stepped-wedge cluster-randomised controlled trial. *Lancet*. 2019;393:1807–1818. doi: 10.1016/S0140-6736(18)33212-4
67. Staff AC, Benton SJ, von Dadelszen P, Roberts JM, Taylor RN, Powers RW, Charnock-Jones DS, Redman CW. Redefining preeclampsia using placenta-derived biomarkers. *Hypertension*. 2013;61:932–942. doi: 10.1161/HYPERTENSIONAHA.111.00250
68. Paauw ND, Luijken K, Franx A, Verhaar MC, Lely AT. Long-term renal and cardiovascular risk after preeclampsia: towards screening and prevention. *Clin Sci (Lond)*. 2016;130:239–246. doi: 10.1042/CS20150567
69. Thangaratnam S, Rogozinska E, Jolly K, Glinkowski S, Roseboom T, Tomlinson JW, Kunz R, Mol BW, Coomarasamy A, Khan KS. Effects of interventions in pregnancy on maternal weight and obstetric outcomes: meta-analysis of randomised evidence. *BMJ*. 2012;344:e2088. doi: 10.1136/bmj.e2088
70. Magro-Malosso ER, Saccone G, Di Tommaso M, Roman A, Berghella V. Exercise during pregnancy and risk of gestational hypertensive disorders: a systematic review and meta-analysis. *Acta Obstet Gynecol Scand*. 2017;96:921–931. doi: 10.1111/aogs.13151
71. Davenport MH, Ruchat SM, Poitras VJ, Jaramillo Garcia A, Gray CE, Barrowman N, Skow RJ, Meah VL, Riske L, Sobierajski F, et al. Prenatal exercise for the prevention of gestational diabetes mellitus and hypertensive disorders of pregnancy: a systematic review and meta-analysis. *Br J Sports Med*. 2018;52:1367–1375. doi: 10.1136/bjsports-2018-099355
72. Mottola MF, Davenport MH, Ruchat SM, Davies GA, Poitras V, Gray C, Jaramillo Garcia A, Barrowman N, Adamo KB, Duggan M, et al. No. 367–2019 Canadian guideline for physical activity throughout pregnancy. *J Obstet Gynaecol Can*. 2018;40:1528–1537. doi: 10.1016/j.jogc.2018.07.001
73. Bartsch E, Medcalf KE, Park AL, Ray JG; High Risk of Pre-Eclampsia Identification Group. Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies. *BMJ*. 2016;353:i1753. doi: 10.1136/bmj.i1753
74. Zhang JJ, Ma XX, Hao L, Liu LJ, Lv JC, Zhang H. A systematic review and meta-analysis of outcomes of pregnancy in CKD and CKD outcomes in pregnancy. *Clin J Am Soc Nephrol*. 2015;10:1964–1978. doi: 10.2215/CJN.09250914
75. Santos S, Voerman E, Amiano P, Barros H, Beilin LJ, Bergström A, Charles MA, Chatzi L, Chevrier C, Chrousos GP, et al. Impact of maternal body mass index and gestational weight gain on pregnancy complications: an individual participant data meta-analysis of European, North American and Australian cohorts. *BJOG*. 2019;126:984–995. doi: 10.1111/1471-0528.15661
76. Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. *BMJ*. 2005;330:565. doi: 10.1136/bmj.38380.674340.E0
77. Ross KM, Dunkel Schetter C, McLemore MR, Chambers BD, Paynter RA, Baer R, Feuer SK, Flowers E, Karasek D, Pantell M, et al. Socioeconomic status, preeclampsia risk and gestational length in Black and White women. *J Racial Ethn Health Disparities*. 2019;6:1182–1191. doi: 10.1007/s40615-019-00619-3
78. Lisonkova S, Joseph KS. Incidence of preeclampsia: risk factors and outcomes associated with early- versus late-onset disease. *Am J Obstet Gynecol*. 2013;209:544.e1–544.e12.
79. Silva LM, Coolman M, Steegers EA, Jaddoe VW, Moll HA, Hofman A, Mackenbach JP, Raat H. Low socioeconomic status is a risk factor for preeclampsia: the Generation R Study. *J Hypertens*. 2008;26:1200–1208. doi: 10.1097/HJH.0b013e328282fcc36e
80. Wu DD, Gao L, Huang O, Ullah K, Guo MX, Liu Y, Zhang J, Chen L, Fan JX, Sheng JZ, et al. Increased adverse pregnancy outcomes associated with stage 1 hypertension in a low-risk cohort: evidence from 47 874 cases. *Hypertension*. 2020;75:772–780. doi: 10.1161/HYPERTENSIONAHA.119.14252
81. Johnson S, Liu B, Kalafat E, Thilaganathan B, Khalil A. Maternal and perinatal outcomes of white coat hypertension during pregnancy: a systematic review and meta-analysis. *Hypertension*. 2020;76:157–166. doi: 10.1161/HYPERTENSIONAHA.119.14627
82. Hauth JC, Clifton RG, Roberts JM, Myatt L, Spong CY, Leveno KJ, Varner MW, Wapner RJ, Thorp JM Jr, Mercer BM, et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Maternal insulin resistance and preeclampsia. *Am J Obstet Gynecol*. 2011;204:327.e1–327.e3276.
83. Östlund I, Haglund B, Hanson U. Gestational diabetes and preeclampsia. *Eur J Obstet Gynecol Reprod Biol*. 2004;113:12–16.
84. Tangren JS, Adnan WAHWM, Powe CE, Ecker J, Bramham K, Hladunewich MA, Ankers E, Karumanchi SA, Thadhani R. Risk of preeclampsia and pregnancy complications in women with a history of acute kidney injury. *Hypertension*. 2018;72:451–459. doi: 10.1161/HYPERTENSIONAHA.118.11161
85. Männistö T, Mendola P, Grewal J, Xie Y, Chen Z, Laughon SK. Thyroid diseases and adverse pregnancy outcomes in a contemporary US cohort. *J Clin Endocrinol Metab*. 2013;98:2725–2733. doi: 10.1210/jc.2012-4233
86. Jauniaux E. Partial moles: from postnatal to prenatal diagnosis. *Placenta*. 1999;20:379–388. doi: 10.1053/plac.1999.0390
87. Tuohy JF, James DK. Pre-eclampsia and trisomy 13. *Br J Obstet Gynaecol*. 1992;99:891–894. doi: 10.1111/j.1471-0528.1992.tb14436.x

88. Williams FJ, Broughton Pipkin F. The genetics of pre-eclampsia and other hypertensive disorders of pregnancy. *Best Pract Res Clin Obstet Gynaecol*. 2011;25:405–417. doi: 10.1016/j.bpobgyn.2011.02.007
89. McGinnis R, Steinthorsdottir V, Williams NO, Thorleifsson G, Shooter S, Hjartardottir S, Bumpstead S, Stefansdottir L, Hildyard L, Sigurdsson JK, et al; FINNPEC Consortium; GOPEC Consortium. Variants in the fetal genome near FLT1 are associated with risk of preeclampsia. *Nat Genet*. 2017;49:1255–1260. doi: 10.1038/ng.3895
90. Masoudian P, Nasr A, de Nanassy J, Fung-Kee-Fung K, Bainbridge SA, El Demellawy D. Oocyte donation pregnancies and the risk of pre-eclampsia or gestational hypertension: a systematic review and meta-analysis. *Am J Obstet Gynecol*. 2016;214:328–339. doi: 10.1016/j.ajog.2015.11.020
91. Hercus A, Dekker G, Leemaqz S. Primipaternity and birth interval: independent risk factors for preeclampsia. *J Matern-Fetal Neonatal Med*. 2020;33:303–306. doi: 10.1080/14767058.2018.1489794
92. Cormick G, Betrán AP, Ciapponi A, Hall DR, Hofmeyr GJ; Calcium and Pre-Eclampsia Study Group. Inter-pregnancy interval and risk of recurrent pre-eclampsia: systematic review and meta-analysis. *Reprod Health*. 2016;13:83. doi: 10.1186/s12978-016-0197-x
93. Aukes AM, Yurtsever FN, Boutin A, Visser MC, de Groot CJM. Associations between migraine and adverse pregnancy outcomes: systematic review and meta-analysis. *Obstet Gynecol Surv*. 2019;74:738–748. doi: 10.1097/OGX.0000000000000738
94. Di Mascio D, Saccone G, Bellussi F, Vitagliano A, Berghella V. Type of paternal sperm exposure before pregnancy and the risk of preeclampsia: a systematic review. *Eur J Obstet Gynecol Reprod Biol*. 2020;251:246–253. doi: 10.1016/j.ejogrb.2020.05.065
95. Wikström AK, Stephansson O, Cnattingius S. Tobacco use during pregnancy and preeclampsia risk: effects of cigarette smoking and snuff. *Hypertension*. 2010;55:1254–1259. doi: 10.1161/HYPERTENSIONAHA.109.147082
96. England L, Zhang J. Smoking and risk of preeclampsia: a systematic review. *Front Biosci*. 2007;12:2471–2483. doi: 10.2741/2248
97. ACOG Committee Opinion No. 743: low-dose aspirin use during pregnancy. *Obstet Gynecol*. 2018;132:e44–e52. doi: 10.1097/AOG.0000000000002708
98. LeFevre ML, US Preventive Services Task Force. Low-dose aspirin use for the prevention of morbidity and mortality from preeclampsia: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med*. 2014;161:819–826. doi: 10.7326/M14-1884
99. Askie LM, Duley L, Henderson-Smart DJ, Stewart LA; PARIS Collaborative Group. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. *Lancet*. 2007;369:1791–1798. doi: 10.1016/S0140-6736(07)60712-0
100. Duley L, Meher S, Hunter KE, Seidler AL, Askie LM. Antiplatelet agents for preventing pre-eclampsia and its complications. *Cochrane Database Syst Rev*. 2019;2019:CD004659. doi: 10.1002/14651858.CD004659.pub2
101. Poon LC, Wright D, Rolnik DL, Syngelaki A, Delgado JL, Tsokaki T, Leipold G, Akolekar R, Shearing S, De Stefani L, et al. Aspirin for evidence-based preeclampsia prevention trial: effect of aspirin in prevention of preterm preeclampsia in subgroups of women according to their characteristics and medical and obstetrical history. *Am J Obstet Gynecol*. 2017;217:585.e1–585.e5. doi: 10.1016/j.ajog.2017.07.038
102. Costantine MM, Cleary K, Hebert MF, Ahmed MS, Brown LM, Ren Z, Easterling TR, Haas DM, Haneline LS, Caritis SN, et al. Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: a pilot randomized controlled trial. *Am J Obstet Gynecol*. 2016;214:720.e1–720.e17. doi: 10.1016/j.ajog.2015.12.038
103. US National Institute of Health, US National Library of Medicine. Accessed July 10, 2020. <https://clinicaltrials.gov/ct2/results?type=Intr&cond=pravastatin+AND+%22Hypertension%2C+Pregnancy-Induced%22&gndr=F+emale&age=1>
104. Brownfoot FC, Hastie R, Hannan NJ, Cannon P, Tuohy L, Parry LJ, Senadheera S, Illanes SE, Kaitu'u-Lino Tu J, Tong S. Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction. *Am J Obstet Gynecol*. 2016;214:356.e1–356.e15. doi: 10.1016/j.ajog.2015.12.019
105. Kirkland JL, Tchkonja T. Cellular senescence: a translational perspective. *EBioMedicine*. 2017;21:21–28. doi: 10.1016/j.ebiom.2017.04.013
106. Romero R, Erez O, Hüttemann M, Maymon E, Panaitescu B, Conde-Agudelo A, Pacora P, Yoon BH, Grossman LI. Metformin, the aspirin of the 21st century: its role in gestational diabetes mellitus, prevention of preeclampsia and cancer, and the promotion of longevity. *Am J Obstet Gynecol*. 2017;217:282–302. doi: 10.1016/j.ajog.2017.06.003
107. Bello NA, Woolley JJ, Cleary KL, Falzon L, Alpert BS, Oparil S, Cutter G, Wapner R, Muntner P, Tita AT, et al. Accuracy of blood pressure measurement devices in pregnancy: a systematic review of validation studies. *Hypertension*. 2018;71:326–335. doi: 10.1161/HYPERTENSIONAHA.117.10295
108. Pipe MA, Evans CV, Burda BU, Margolis KL, O'Connor E, Smith N, Webber E, Perdue LA, Bigler KD, Whitlock EP. *Screening for High Blood Pressure in Adults: A Systematic Evidence Review for the U.S. Preventive Services Task Force*. Agency for Healthcare Research and Quality; 2014.
109. Bello NA, Miller E, Cleary K, Wapner R, Shimbo D, Tita AT. Out of office blood pressure measurement in pregnancy and the postpartum period. *Curr Hypertens Rep*. 2018;20:101. doi: 10.1007/s11906-018-0901-z
110. Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, Hall DR, Warren CE, Adoyi G, Ishaku S; International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice. *Hypertension*. 2018;72:24–43. doi: 10.1161/HYPERTENSIONAHA.117.10803
111. Tucker KL, Bankhead C, Hodgkinson J, Roberts N, Stevens R, Heneghan C, Rey É, Lo C, Chandiramani M, Taylor RS, et al. How do home and clinic blood pressure readings compare in pregnancy? *Hypertension*. 2018;72:686–694. doi: 10.1161/HYPERTENSIONAHA.118.10917
112. Rothwell PM, Howard SC, Dolan E, O'Brien E, Dobson JE, Dahlöf B, Sever PS, Poulter NR. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. *Lancet*. 2010;375:895–905. doi: 10.1016/S0140-6736(10)60308-X.
113. Shimbo D, Newman JD, Aragaki AK, LaMonte MJ, Bavy AA, Allison M, Manson JE, Wassertheil-Smoller S. Association between annual visit-to-visit blood pressure variability and stroke in postmenopausal women: data from the Women's Health Initiative. *Hypertension*. 2012;60:625–630. doi: 10.1161/HYPERTENSIONAHA.112.193094
114. Chang TI, Reboussin DM, Chertow GM, Cheung AK, Cushman WC, Kostis WJ, Parati G, Raj D, Riesen E, Shapiro B, et al; SPRINT Research Group. Visit-to-visit office blood pressure variability and cardiovascular outcomes in SPRINT (Systolic Blood Pressure Intervention Trial). *Hypertension*. 2017;70:751–758. doi: 10.1161/HYPERTENSIONAHA.117.09788
115. Vidal-Petiot E, Stebbins A, Chiswell K, Ardisino D, Aylward PE, Cannon CP, Ramos Corrales MA, Held C, López-Sendón JL, Stewart RAH, et al; STABILITY Investigators. Visit-to-visit variability of blood pressure and cardiovascular outcomes in patients with stable coronary heart disease: insights from the STABILITY trial. *Eur Heart J*. 2017;38:2813–2822. doi: 10.1093/eurheartj/ehx250
116. Mancia G, Facchetti R, Parati G, Zanchetti A. Visit-to-visit blood pressure variability, carotid atherosclerosis, and cardiovascular events in the European Lacidipine Study on Atherosclerosis. *Circulation*. 2012;126:569–578. doi: 10.1161/CIRCULATIONAHA.112.107565
117. Wang H, Li M, Xie SH, Oyang YT, Yin M, Bao B, Chen ZY, Yin XP. Visit-to-visit systolic blood pressure variability and stroke risk: a systematic review and meta-analysis. *Curr Med Sci*. 2019;39:741–747. doi: 10.1007/s11596-019-2100-9
118. Ma Y, Song A, Viswanathan A, Blacker D, Vernooij MW, Hofman A, Papatheodorou S. Blood pressure variability and cerebral small vessel disease: a systematic review and meta-analysis of population-based cohorts. *Stroke*. 2020;51:82–89. doi: 10.1161/STROKEAHA.119.026739
119. Kim SA, Lee JD, Park JB. Differences in visit-to-visit blood pressure variability between normotensive and hypertensive pregnant women. *Hypertens Res*. 2019;42:67–74. doi: 10.1038/s41440-018-0112-7
120. Magee LA, Singer J, Lee T, McManus RJ, Lay-Flurrie S, Rey E, Chappell LC, Myers J, Logan AG, von Döbeln P. Are blood pressure level and variability related to pregnancy outcome? Analysis of control of hypertension in pregnancy study data. *Pregnancy Hypertens*. 2020;19:87–93. doi: 10.1016/j.preghy.2019.12.002
121. Malha L, August P. Secondary hypertension in pregnancy. *Curr Hypertens Rep*. 2015;17:53.
122. Corsello SM, Paragliola RM. Evaluation and management of endocrine hypertension during pregnancy. *Endocrinol Metab Clin North Am*. 2019;48:829–842. doi: 10.1016/j.ecl.2019.08.011
123. Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Division of Nutrition Physical Activity and Obesity. Data, trends and maps. Accessed February 26, 2021. <https://www.cdc.gov/nccdphp/dnpao/data-trends-maps/>
124. Dominguez JE, Habib AS, Krystal AD. A review of the associations between obstructive sleep apnea and hypertensive disorders of pregnancy

- and possible mechanisms of disease. *Sleep Med Rev*. 2018;42:37–46. doi: 10.1016/j.smrv.2018.05.004
125. Hypertension in pregnancy: report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. *Obstet Gynecol*. 2013;122:1122–1131. doi: 10.1097/01.AOG.0000437382.03963.88
  126. Davis NL, Smoots AN, Goodman DA. Pregnancy-related deaths: data from 14 U.S. maternal mortality review committees, 2008–2017. Accessed December 2, 2021. <https://www.cdc.gov/reproductivehealth/maternal-mortality/erase-mm/mmr-data-brief.html>
  127. Goel A, Maski MR, Bajracharya S, Wenger JB, Zhang D, Salahuddin S, Shahul SS, Thadhani R, Seely EW, Karumanchi SA, et al. Epidemiology and mechanisms of de novo and persistent hypertension in the postpartum period. *Circulation*. 2015;132:1726–1733. doi: 10.1161/CIRCULATIONAHA.115.015721
  128. Ditisheim A, Wuerzner G, Ponte B, Vial Y, Irion O, Burnier M, Boulvain M, Pechère-Bertschi A. Prevalence of hypertensive phenotypes after pre-eclampsia: a prospective cohort study. *Hypertension*. 2018;71:103–109. doi: 10.1161/HYPERTENSIONAHA.117.09799
  129. Hauspurg A, Lemon LS, Quinn BA, Binstock A, Larkin J, Beigi RH, Watson AR, Simhan HN. A postpartum remote hypertension monitoring protocol implemented at the hospital level. *Obstet Gynecol*. 2019;134:685–691. doi: 10.1097/AOG.0000000000003479
  130. Lopes Perdigao J, Chinthala S, Mueller A, Minhas R, Ramadan H, Nasim R, Naseem H, Young D, Shahul S, Chan SL, et al. Angiogenic factor estimation as a warning sign of preeclampsia-related peripartum morbidity among hospitalized patients. *Hypertension*. 2019;73:868–877. doi: 10.1161/HYPERTENSIONAHA.118.12205
  131. Janzarik WG, Jacob J, Katagis E, Markfeld-Erol F, Sommerlade L, Wuttke M, Reinhard M. Preeclampsia postpartum: Impairment of cerebral autoregulation and reversible cerebral hyperperfusion. *Pregnancy Hypertens*. 2019;17:121–126. doi: 10.1016/j.preghy.2019.05.019
  132. Lopes Perdigao J, Lewey J, Hirshberg A, Koelper N, Srinivas SK, Elovitz MA, Levine LD. Furosemide for accelerated recovery of blood pressure postpartum in women with a hypertensive disorder of pregnancy: a randomized controlled trial. *Hypertension*. 2021;77:1517–1524. doi: 10.1161/HYPERTENSIONAHA.120.16133
  133. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. *Ann Intern Med*. 1994;121:289–300. doi: 10.7326/0003-4819-121-4-199408150-00011
  134. Ruschitzka F, Borer JS, Krum H, Flammer AJ, Yeomans ND, Libby P, Lüscher TF, Solomon DH, Husni ME, Graham DY, et al. Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement) trial. *Eur Heart J*. 2017;38:3282–3292. doi: 10.1093/eurheartj/ehx508
  135. Mulkerrin EC, Clark BA, Epstein FH. Increased salt retention and hypertension from non-steroidal agents in the elderly. *QJM*. 1997;90:411–415. doi: 10.1093/qjmed/90.6.411
  136. Bellos I, Pergialiotis V, Antsaklis A, Loutradis D, Daskalakis G. Safety of non-steroidal anti-inflammatory drugs in the postpartum period among women with hypertensive disorders of pregnancy: a meta-analysis. *Ultrasound Obstet Gynecol*. 2020;56:329–339. doi: 10.1002/uog.21997
  137. Podymow T, August P. Postpartum course of gestational hypertension and preeclampsia. *Hypertens Pregnancy*. 2010;29:294–300. doi: 10.3109/10641950902777747
  138. Lopes Perdigao J, Hirshberg A, Koelper N, Srinivas SK, Sammel MD, Levine LD. Postpartum blood pressure trends are impacted by race and BMI. *Pregnancy Hypertens*. 2020;20:14–18. doi: 10.1016/j.preghy.2020.02.006
  139. Vasan RS, Larson MG, Leip EP, Evans JC, O'Donnell CJ, Kannel WB, Levy D. Impact of high-normal blood pressure on the risk of cardiovascular disease. *N Engl J Med*. 2001;345:1291–1297. doi: 10.1056/NEJMoa003417
  140. Franklin SS, Gustin W, Wong ND, Larson MG, Weber MA, Kannel WB, Levy D. Hemodynamic patterns of age-related changes in blood pressure. *Circulation*. 1997;96:308–315. doi: 10.1161/01.cir.96.1.308
  141. Lenfant C, Chobanian AV, Jones DW, Roccella EJ; Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Seventh report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7): resetting the hypertension sails. *Hypertension*. 2003;41:1178–1179. doi: 10.1161/01.HYP.0000075790.33892.AE
  142. *WHO Recommendations: Drug Treatment for Severe Hypertension in Pregnancy*. World Health Organization; 2018.
  143. *WHO Recommendations on Drug Treatment for Non-Severe Hypertension in Pregnancy*. World Health Organization; 2020.
  144. National Institute for Health and Care Excellence. Hypertension in pregnancy: diagnosis and management: NICE guideline [NG133]. Accessed July 29, 2019. <https://www.nice.org.uk/guidance/ng133/chapter/Recommendations#management-of-chronic-hypertension-in-pregnancy>
  145. Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P; Canadian Hypertensive Disorders of Pregnancy Working Group. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. *J Obstet Gynaecol Can*. 2014;36:416–441. doi: 10.1016/s1701-2163(15)30588-0
  146. Rabi DM, McBrien KA, Sapir-Pichhadze R, Nakhla M, Ahmed SB, Dumanski SM, Butalia S, Leung AA, Harris KC, Cloutier L, et al. Hypertension Canada's 2020 comprehensive guidelines for the prevention, diagnosis, risk assessment, and treatment of hypertension in adults and children. *Can J Cardiol*. 2020;36:596–624. doi: 10.1016/j.cjca.2020.02.086
  147. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomström-Lundqvist C, Cifková R, De Bonis M, Iung B, Johnson MR, Kintscher U, Kranke P, et al; European Scientific Document Group. 2018 ESC guidelines for the management of cardiovascular diseases during pregnancy: the Task Force for the Management of Cardiovascular Diseases During Pregnancy of the European Society of Cardiology (ESC). *Eur Heart J*. 2018;39:3165–3241. doi: 10.1093/eurheartj/ehy340
  148. Lowe SA, Bowyer L, Lust K, McMahon LP, Morton M, North RA, Paech M, Said JM. SOMANZ guidelines for the management of hypertensive disorders of pregnancy 2014. *Aust N Z J Obstet Gynaecol*. 2015;55:e1–e29. doi: 10.1111/ajo.12399
  149. Butalia S, Audibert F, Côté AM, Firoz T, Logan AG, Magee LA, Mundle W, Rey E, Rabi DM, Daskalopoulou SS, et al; Hypertension Canada. Hypertension Canada's 2018 guidelines for the management of hypertension in pregnancy. *Can J Cardiol*. 2018;34:526–531. doi: 10.1016/j.cjca.2018.02.021
  150. ACOG Practice Bulletin No. 212: pregnancy and heart disease. *Obstet Gynecol*. 2019;133:e320–e356. doi: 10.1097/AOG.0000000000003243
  151. Ministry of Health New Zealand. Diagnosis and treatment of hypertension and pre-eclampsia in pregnancy in New Zealand: a clinical practice guideline. 2018. Accessed February 26, 2021. <https://www.health.govt.nz/system/files/documents/publications/diagnosis-and-treatment-of-hypertension-and-pre-eclampsia-in-pregnancy-in-new-zealand-v3.pdf>
  152. Abalos E, Duley L, Steyn DW, Gialdini C. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. *Cochrane Database Syst Rev*. 2018;10:CD002252. doi: 10.1002/14651858.CD002252.pub4
  153. Minhas R, Young D, Naseem R, Mueller A, Chinthala S, Perdigao JL, Yeo KJ, Chan SL, Tung A, White JB, et al. Association of antepartum blood pressure levels and angiogenic profile among women with chronic hypertension. *Pregnancy Hypertens*. 2018;14:110–114. doi: 10.1016/j.preghy.2018.09.003
  154. Tanaka M, Jaamaa G, Kaiser M, Hills E, Soim A, Zhu M, Shcherbatykh IY, Samelson R, Bell E, Zdeb M, et al. Racial disparity in hypertensive disorders of pregnancy in New York State: a 10-year longitudinal population-based study. *Am J Public Health*. 2007;97:163–170. doi: 10.2105/AJPH.2005.068577
  155. Heimberger S, Perdigao JL, Mueller A, Shahul S, Naseem H, Minhas R, Chintala S, Rana S. Effect of blood pressure control in early pregnancy and clinical outcomes in African American women with chronic hypertension. *Pregnancy Hypertens*. 2020;20:102–107. doi: 10.1016/j.preghy.2020.03.008
  156. Allen SE, Tita A, Anderson S, Biggio JR, Harper DLM. Is use of multiple antihypertensive agents to achieve blood pressure control associated with adverse pregnancy outcomes? *J Perinatol*. 2017;37:340–344. doi: 10.1038/jp.2016.247
  157. Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A, Pessin MS, Lamy C, Mas JL, Caplan LR. A reversible posterior leukoencephalopathy syndrome. *N Engl J Med*. 1996;334:494–500. doi: 10.1056/NEJM199602223340803
  158. Brewer J, Owens MY, Wallace K, Reeves AA, Morris R, Khan M, LaMarca B, Martin JN, Jr. Posterior reversible encephalopathy syndrome in 46 of 47 patients with eclampsia. *Am J Obstet Gynecol*. 2013;208:468.e1–468.e6. doi: 10.1016/j.ajog.2013.02.015
  159. Easterling TR. Post Control of Hypertension in Pregnancy Study (CHIPS). *Hypertension*. 2016;68:36–38.
  160. Fisher SC, Kim SY, Sharma AJ, Rochat R, Morrow B. Is obesity still increasing among pregnant women? Prepregnancy obesity trends in 20 states, 2003–2009. *Prev Med*. 2013;56:372–378. doi: 10.1016/j.ypmed.2013.02.015

161. Yuen L, Saeedi P, Riaz M, Karuranga S, Divakar H, Levitt N, Yang X, Simmons D. Projections of the prevalence of hyperglycaemia in pregnancy in 2019 and beyond: results from the International Diabetes Federation Diabetes Atlas, 9th edition. *Diabetes Res Clin Pract*. 2019;157:107841. doi: 10.1016/j.diabres.2019.107841
162. Crude birth rates, fertility rates, and birth rates, by age, race, and Hispanic origin of mother: United States, selected years 1950–2017. Accessed December 2, 2021. [https://www.cdc.gov/nchs/hus/contents2018.htm#Table\\_001](https://www.cdc.gov/nchs/hus/contents2018.htm#Table_001)
163. Elkayam U, Goland S, Pieper PG, Silverside CK. High-risk cardiac disease in pregnancy: part I. *J Am Coll Cardiol*. 2016;68:396–410. doi: 10.1016/j.jacc.2016.05.048
164. Murray Horwitz ME, Rodriguez MI, Dissanayake M, Carmichael SL, Snowden JM. Postpartum health risks among women with hypertensive disorders of pregnancy, California 2008–2012. *J Hypertens*. 2021;39:1009–1017. doi: 10.1097/HJH.0000000000002711
165. SMFM Publications Committee. SMFM statement: benefit of antihypertensive therapy for mild-to-moderate chronic hypertension during pregnancy remains uncertain. *Am J Obstet Gynecol*. 2015;213:3–4. doi: 10.1016/j.jagob.2015.04.013
166. Fitton CA, Steiner MFC, Aucott L, Pell JP, Mackay DF, Fleming M, McLay JS. In-utero exposure to antihypertensive medication and neonatal and child health outcomes: a systematic review. *J Hypertens*. 2017;35:2123–2137. doi: 10.1097/HJH.0000000000001456
167. Magee LA, Elran E, Bull SB, Logan A, Koren G. Risks and benefits of  $\beta$ -receptor blockers for pregnancy hypertension: overview of the randomized trials. *Eur J Am J Obstet Gynecol Reprod Biol*. 2000;88:15–26. doi: 10.1016/s0301-2115(99)00113-x
168. Bellos I, Pergialiotis V, Papapanagiotou A, Loutradis D, Daskalakis G. Comparative efficacy and safety of oral antihypertensive agents in pregnant women with chronic hypertension: a network metaanalysis. *Am J Obstet Gynecol*. 2020;223:525–537. doi: 10.1016/j.jagob.2020.03.016
169. Lydakis C, Lip GY, Beevers M, Beevers DG. Atenolol and fetal growth in pregnancies complicated by hypertension. *Am J Hypertens*. 1999;12:541–547. doi: 10.1016/s0895-7061(99)00031-x
170. Meidahl Petersen K, Jimenez-Solem E, Andersen JT, Petersen M, Brødbæk K, Køber L, Torp-Pedersen C, Poulsen HE.  $\beta$ -Blocker treatment during pregnancy and adverse pregnancy outcomes: a nationwide population-based cohort study. *BMJ Open*. 2012;2:e001185. doi: 10.1136/bmjopen-2012-001185
171. Duley L, Meher S, Jones L. Drugs for treatment of very high blood pressure during pregnancy. *Cochrane Database Syst Rev*. 2013;CD001449. doi: 10.1002/14651858.CD001449.pub3
172. Chiriaco M, Pateras K, Virdis A, Charakida M, Kyriakopoulou D, Nannipieri M, Emdin M, Tsioufis K, Taddei S, Masi S, et al. Association between blood pressure variability, cardiovascular disease and mortality in type 2 diabetes: a systematic review and meta-analysis. *Diabetes Obes Metab*. 2019;21:2587–2598. doi: 10.1111/dom.13828
173. Easterling T, Mundle S, Bracken H, Parvekar S, Mool S, Magee LA, von Dadelszen P, Shochet T, Winikoff B. Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial. *Lancet*. 2019;394:1011–1021. doi: 10.1016/S0140-6736(19)31282-6
174. Nij Bijvank SW, Duvekot JJ. Nicardipine for the treatment of severe hypertension in pregnancy: a review of the literature. *Obstet Gynecol Survey*. 2010;65:341–347. doi: 10.1097/OGX.0b013e3181e2c795
175. Tuimala R, Punnonen R, Kauppila E. Clonidine in the treatment of hypertension during pregnancy. *Ann Chir Gynaecol Suppl*. 1985;197:47–50.
176. Veena P, Perivela L, Raghavan SS. Furosemide in postpartum management of severe preeclampsia: a randomized controlled trial. *Hypertens Pregnancy*. 2017;36:84–89. doi: 10.1080/10641955.2016.1239735
177. Collins R, Yusuf S, Peto R. Overview of randomised trials of diuretics in pregnancy. *Br Med J (Clin Res Ed)*. 1985;290:17–23. doi: 10.1136/bmj.290.6461.17
178. Bateman BT, Huybrechts KF, Fischer MA, Seely EW, Ecker JL, Oberg AS, Franklin JM, Mogun H, Hernandez-Diaz S. Chronic hypertension in pregnancy and the risk of congenital malformations: a cohort study. *Am J Obstet Gynecol*. 2015;212:337.e1–337.e14. doi: 10.1016/j.jagob.2014.09.031
179. van Gelder MM, Van Bennekom CM, Louik C, Werler MM, Roeleveld N, Mitchell AA. Maternal hypertensive disorders, antihypertensive medication use, and the risk of birth defects: a case-control study. *BJOG*. 2015;122:1002–1009. doi: 10.1111/1471-0528.13138
180. Cockburn J, Moar VA, Ounsted M, Redman CW. Final report of study on hypertension during pregnancy: the effects of specific treatment on the growth and development of the children. *Lancet*. 1982;1:647–649. doi: 10.1016/s0140-6736(82)92202-4
181. Bortolus R, Ricci E, Chatenoud L, Parazzini F. Nifedipine administered in pregnancy: effect on the development of children at 18 months. *BJOG*. 2000;107:792–794. doi: 10.1111/j.1471-0528.2000.tb13342.x
182. Reynolds B, Butters L, Evans J, Adams T, Rubin PC. First year of life after the use of atenolol in pregnancy associated hypertension. *Arch Dis Child*. 1984;59:1061–1063. doi: 10.1136/adc.59.11.1061
183. Sverrisson FA, Bateman BT, Aspelund T, Skulason S, Zoega H. Preeclampsia and academic performance in children: a nationwide study from Iceland. *PLoS One*. 2018;13:e0207884. doi: 10.1371/journal.pone.0207884
184. Chan WS, Koren G, Barrera M, Rezvani M, Knittel-Keren D, Nulman I. Neurocognitive development of children following in-utero exposure to labetalol for maternal hypertension: a cohort study using a prospectively collected database. *Hypertens Pregnancy*. 2010;29:271–283. doi: 10.3109/10641950902777705
185. Boesen EI. Consequences of in-utero exposure to antihypertensive medication: the search for definitive answers continues. *J Hypertens*. 2017;35:2161–2164. doi: 10.1097/HJH.0000000000001486
186. Mito A, Murashima A, Wada Y, Miyasato-Isoda M, Kamiya CA, Waguri M, Yoshimatsu J, Yakuwa N, Watanabe O, Suzuki T, et al. Safety of amlodipine in early pregnancy. *J Am Heart Assoc*. 2019;8:e012093. doi: 10.1161/JAHA.119.012093
187. Horvath JS, Phippard A, Korda A, Henderson-Smart DJ, Child A, Tiller DJ. Clonidine hydrochloride: a safe and effective antihypertensive agent in pregnancy. *Obstet Gynecol*. 1985;66:634–638.
188. Buawangpong N, Teekachunhatean S, Koonrungsesomboon N. Adverse pregnancy outcomes associated with first-trimester exposure to angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers: a systematic review and meta-analysis. *Pharmacol Res Perspect*. 2020;8:e00644. doi: 10.1002/prp2.644
189. Touch Neurology. The Organization of Teratology Information Specialists (OTIS)/MotherToBaby. 2021. Accessed May 26, 2021. <https://touchneurology.com/supplier/the-organization-of-teratology-information-specialists-otis-mothertobaby/>
190. Gareau S, López-De Fede A, Loudermilk BL, Cummings TH, Hardin JW, Picklesimer AH, Crouch E, Covington-Kolb S. Group prenatal care results in Medicaid savings with better outcomes: a propensity score analysis of CenteringPregnancy participation in South Carolina. *Matern Child Health J*. 2016;20:1384–1393. doi: 10.1007/s10995-016-1935-y
191. Mhyre JM, D'Oria R, Hameed AB, Lappen JR, Holley SL, Hunter SK, Jones RL, King JC, D'Alton ME. The maternal early warning criteria: a proposal from the national partnership for maternal safety. *J Obstet Gynecol Neonatal Nurs*. 2014;43:771–779. doi: 10.1111/1552-6909.12504
192. Clark SL, Christmas JT, Frye DR, Meyers JA, Perlin JB. Maternal mortality in the United States: predictability and the impact of protocols on fatal postcesarean pulmonary embolism and hypertension-related intracranial hemorrhage. *Am J Obstet Gynecol*. 2014;211:32.e1–32.e9. doi: 10.1016/j.jagob.2014.03.031
193. World Health Organization. Trends in maternal mortality 2000 to 2017: estimates by WHO, UNICEF, UNFPA, World Bank Group and the United Nations Population Division. 2021. Accessed February 26, 2021. [https://www.unfpa.org/sites/default/files/pub-pdf/Maternal\\_mortality\\_report.pdf](https://www.unfpa.org/sites/default/files/pub-pdf/Maternal_mortality_report.pdf)
194. Petersen EE, Davis NL, Goodman D, Cox S, Sylverson C, Seed K, Shapiro-Mendoza C, Callaghan WM, Barfield W. Racial/ethnic disparities in pregnancy related deaths, United States, 2007–2016. *MMWR Morb Mortal Wkly Rep*. 2019;68:762–765. doi: 10.15585/mmwr.mm6835a3
195. Wang E, Glazer KB, Howell EA, Janevic TM. Social determinants of pregnancy-related mortality and morbidity in the United States: a systematic review. *Obstet Gynecol*. 2020;135:896–915. doi: 10.1097/AOG.0000000000003762
196. Zamora-Kapoor A, Nelson LA, Buchwald DS, Walker LR, Mueller BA. Preeclampsia in American Indians/Alaska Natives and Whites: the significance of body mass index. *Matern Child Health J*. 2016;20:2233–2238. doi: 10.1007/s10995-016-2126-6
197. Redman EK, Hauspurg A, Hubel CA, Roberts JM, Jayabalan A. Clinical course, associated factors, and blood pressure profile of delayed-onset postpartum preeclampsia. *Obstet Gynecol*. 2019;134:995–1001. doi: 10.1097/AOG.0000000000003508
198. Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Cheng S, Delling FN, et al; on behalf of the American Heart Association Council on Epidemiology and

- Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2021 update: a report from the American Heart Association. *Circulation*. 2021;143:e254–e743. doi: 10.1161/CIR.0000000000000950
199. Thakoordeen-Reddy S, Winkler C, Moodley J, David V, Binns-Roemer E, Ramsuran V, Naicker T. Maternal variants within the apolipoprotein L1 gene are associated with preeclampsia in a South African cohort of African ancestry. *Eur J Obstet Gynecol Reprod Biol*. 2020;246:129–133. doi: 10.1016/j.ejogrb.2020.01.034
  200. Loisel DA, Billstrand C, Murray K, Patterson K, Chaiworapongsa T, Romero R, Ober C. The maternal HLA-G 1597ΔC null mutation is associated with increased risk of pre-eclampsia and reduced HLA-G expression during pregnancy in African-American women. *Mol Hum Reprod*. 2013;19:144–152. doi: 10.1093/molehr/gas041
  201. Carr A, Kershaw T, Brown H, Allen T, Small M. Hypertensive disease in pregnancy: an examination of ethnic differences and the Hispanic paradox. *J Neonatal Perinatal Med*. 2013;6:11–15. doi: 10.3233/NPM-1356111
  202. Gyamfi-Bannerman C, Pandita A, Miller EC, Boehme AK, Wright JD, Siddiq Z, D'Alton ME, Friedman AM. Preeclampsia outcomes at delivery and race. *J Matern Fetal Neonatal Med*. 2020;33:3619–3626. doi: 10.1080/14767058.2019.1581522
  203. Bello NA, Zhou H, Cheetham TC, Miller E, Getahun DT, Fassett MJ, Reynolds K. Prevalence of hypertension among pregnant women when using the 2017 American College of Cardiology/American Heart Association blood pressure guidelines and association with maternal and fetal outcomes. *JAMA Netw Open*. 2021;4:e213808. doi: 10.1001/jamanetworkopen.2021.3808
  204. Brown HL, Warner JJ, Gianos E, Gulati M, Hill AJ, Hollier LM, Rosen SE, Rosser ML, Wenger NK. Promoting risk identification and reduction of cardiovascular disease in women through collaboration with obstetricians and gynecologists: a presidential advisory from the American Heart Association and the American College of Obstetricians and Gynecologists. *Circulation*. 2018;137:e843–e852. doi: 10.1161/CIR.0000000000000582